Journal of Molecular Science
Volume 35 Issue 4, Year of Publication 2025, Page 1355-1377
DoI-10.004687/1000-9035.2025.180

Journal of Molecular Science

Journal of Molecular Science
www.jmolecularsci.com ISSN:1000-9035

Recent Advances in the Synthesis and Pharmacological Activities of Benzimidazole and Isoxazole-Based Heterocycles

Shabeena Parveen, Dr Milind Sharad Pande
Department of Pharmaceutical Sciences, IIMT University, Meerut, UP.

Article Information
Received: 28-10-2025
Revised: 16-11-2025
Accepted: 25-11-2025
Published: 21-12-2025

Keywords
Benzimidazole derivatives, isoxazole derivatives, heterocyclic compounds, green synthesis, pharmacological activity, structure–activity relationship, molecular docking, drug design

ABSTRACT

Heterocyclic compounds, particularly benzimidazole and isoxazole derivatives, occupy a prominent place in modern medicinal chemistry due to their structural versatility, diverse reactivity, and broad pharmacological potential. These scaffolds have shown remarkable efficacy in developing therapeutic agents targeting infections, cancer, inflammation, and oxidative stress. The present review provides an integrated analysis of recent advancements in the synthesis, structural modification, and biological evaluation of benzimidazole and isoxazole-based compounds. Classical and modern synthetic strategies including green chemistry, microwave-assisted, and nanocatalytic methodologies have revolutionized their preparation, enabling eco-efficient production and enhanced yields. Structure–activity relationship and computational approaches such as molecular docking and QSAR analyses have elucidated crucial pharmacophoric features influencing enzyme inhibition, receptor binding, and bioavailability. Benzimidazole derivatives demonstrate potent antimicrobial, antiviral, and anticancer activities, whereas isoxazoles exhibit high selectivity and metabolic stability, excelling in anti-inflammatory and antiviral domains. Comparative studies reveal that hybridization of these two scaffolds enhances multitarget activity and reduces drug resistance. Despite significant progress, challenges such as synthetic limitations, toxicity management, and translation to clinical candidates persist. The review highlights the growing relevance of AI-assisted design, sustainable synthesis, and nanotechnology integration to overcome these barriers. Ultimately, benzimidazole and isoxazole derivatives continue to serve as indispensable frameworks for next-generation drug discovery, contributing to more effective and safer therapeutic innovations.

1. INTRODUCTION:

Heterocyclic compounds occupy a central position in medicinal chemistry owing to their wide structural diversity and remarkable biological significance. These molecules, characterized by rings containing at least one heteroatom such as nitrogen, oxygen, or sulfur, form the core frameworks of numerous therapeutic agents. The presence of heteroatoms profoundly influences the electronic distribution, lipophilicity, and hydrogen-bonding capacity of these molecules, thereby enhancing their pharmacological potential. Approximately 70–80% of known drugs and bioactive natural products contain at least one heterocyclic moiety, underscoring their indispensability in drug discovery and development[1, 2].

The versatility of heterocycles arises from their ability to mimic natural substrates, interact with various biological targets, and exhibit a broad range of pharmacological activities including antimicrobial, antiviral, anticancer, anti-inflammatory, antihypertensive, and antitubercular effects. Their rigid and planar structures allow precise alignment with biological receptors, while the introduction of substituents at specific positions enables fine-tuning of potency and selectivity. Heterocyclic scaffolds often enhance metabolic stability, bioavailability, and solubility attributes essential for optimizing drug-like properties[3, 4].

From a synthetic perspective, heterocyclic chemistry provides an expansive platform for the development of novel molecules through conventional and modern methodologies such as multicomponent reactions, microwave-assisted synthesis, and green chemistry approaches. These synthetic advancements have facilitated the rapid exploration of structural diversity and the creation of compound libraries for high-throughput screening[5].

In addition to their pharmaceutical relevance, heterocycles play crucial roles in agrochemicals, dyes, and materials science. However, their greatest impact remains within the pharmaceutical domain, where they serve as key pharmacophores in well-known drugs such as omeprazole (benzimidazole-based proton pump inhibitor), isoniazid (pyridine derivative), and celecoxib (isoxazole-containing anti-inflammatory). This widespread utilization highlights their capacity to modulate diverse biochemical pathways effectively[6].

The heterocyclic compounds represent the foundation of modern medicinal chemistry. Their structural flexibility, synthetic accessibility, and wide-ranging biological activities continue to drive the discovery of safer, more effective therapeutic agents. The ongoing study of heterocyclic scaffolds such as benzimidazole and isoxazole remains crucial for addressing contemporary health challenges and for the rational design of next-generation drugs[7].

1.1 Historical Perspective of Benzimidazole and Isoxazole Discovery:

The discovery and development of benzimidazole and isoxazole heterocycles mark important milestones in the evolution of medicinal chemistry. Both classes of compounds emerged in the late 19th and early 20th centuries as chemists began to explore the relationship between molecular structure and biological activity. Their discovery opened new avenues for designing molecules with diverse pharmacological properties, paving the way for many therapeutic breakthroughs that remain relevant today[8, 9].

Benzimidazole was first synthesized in 1872 by Hoebrecker through the condensation of o-phenylenediamine with formic acid, a reaction that established the fundamental benzimidazole nucleus. Later, Ladenburg refined the method, expanding the understanding of its structural characteristics and reactivity. The simplicity of its synthesis and its structural resemblance to purines biologically important molecules found in DNA and coenzymes attracted early pharmacological interest. In the early 20th century, benzimidazole derivatives began to demonstrate potent biological activities, notably as antiparasitic and antimicrobial agents. A significant breakthrough came with the introduction of thiabendazole, albendazole, and mebendazole, which revolutionized anthelmintic therapy. Subsequently, benzimidazole scaffolds became integral in the development of proton pump inhibitors like omeprazole and antihypertensive drugs such as candesartan, illustrating their broad therapeutic potential[10-12].

Isoxazole, another five-membered heterocycle containing both oxygen and nitrogen atoms, was first reported in 1888 by Claisen and Lowman. Its synthesis involved the cyclization of hydroxylamine with 1,3-diketones or β-ketoesters. The unique aromatic stability and electron distribution of isoxazole attracted significant attention from chemists seeking novel pharmacophores. Early isoxazole derivatives exhibited antimicrobial and anti-inflammatory properties, leading to the synthesis of sulfonamide-isoxazoles and COX-2 inhibitors such as celecoxib and valdecoxib both of which became landmark drugs in pain and inflammation management[13, 14].

Over time, both benzimidazole and isoxazole derivatives have been explored extensively for their structural versatility and biological relevance. Their evolution from simple laboratory curiosities to essential building blocks in modern medicinal chemistry reflects the progress of synthetic techniques and a growing understanding of structure–activity relationships. Today, these heterocyclic systems continue to inspire the design of multifunctional agents targeting infections, cancer, and inflammatory diseases[15].

1.2 Structural Uniqueness and Pharmacophoric Features:

The structural uniqueness and pharmacophoric versatility of benzimidazole and isoxazole derivatives account for their remarkable prominence in medicinal chemistry. Both heterocyclic frameworks possess distinctive electronic and geometric characteristics that enable specific interactions with diverse biological targets, thereby imparting potent and selective pharmacological activities [16].

Benzimidazole, composed of a fusion between a benzene ring and an imidazole moiety, forms a rigid bicyclic system that closely resembles naturally occurring purine bases such as adenine and guanine. This resemblance allows benzimidazole derivatives to interact effectively with nucleic acids, enzymes, and receptors involved in vital cellular processes. The nitrogen atoms at positions 1 and 3 of the imidazole ring serve as potential hydrogen bond donors and acceptors, facilitating strong binding interactions with biological macromolecules. Substitution at positions 2 and 5 on the benzene ring provides vast opportunities for structural modification, enabling fine-tuning of physicochemical and pharmacokinetic properties. This adaptability explains why benzimidazole scaffolds exhibit diverse pharmacological profiles ranging from antimicrobial and anthelmintic to anticancer and antihypertensive activities [17-19].

Isoxazole, a five-membered aromatic ring containing adjacent oxygen and nitrogen heteroatoms, exhibits unique electronic distribution and resonance stabilization. The presence of two heteroatoms within a compact aromatic framework creates regions of high electron density, favoring hydrogen bonding and dipole–dipole interactions with target biomolecules. Isoxazole derivatives are particularly known for their metabolic stability and bioisosteric properties, often serving as replacements for amides, esters, or phenols in drug design to improve pharmacokinetic behavior. Substitutions at the 3- and 5-positions of the isoxazole ring significantly influence biological activity, enabling the creation of selective inhibitors, anti-inflammatory agents, and anticancer compounds [20, 21].

From a pharmacophoric standpoint, both benzimidazole and isoxazole serve as privileged scaffolds structural motifs capable of binding to multiple biological targets with high affinity. Their aromaticity, hydrogen-bonding capabilities, and tunable electronic properties make them ideal cores for hybrid molecule design. The ability to combine these two frameworks into a single hybrid structure further enhances molecular diversity and offers promising opportunities for multitarget drug discovery. Collectively, their structural rigidity, electronic versatility, and pharmacophoric richness establish benzimidazole and isoxazole as indispensable building blocks in contemporary medicinal chemistry[22, 23].

This review aims to provide a comprehensive overview of recent advances in the synthesis, structural modifications, and pharmacological activities of benzimidazole and isoxazole-based heterocycles. It highlights the significance of these scaffolds as privileged structures in drug design, summarizes key synthetic strategies, and examines their diverse biological properties. The review also discusses structure–activity relationships (SAR), current research trends, and future perspectives for developing potent, selective, and safer therapeutic agents based on these heterocyclic frameworks.

Despite the remarkable therapeutic success of existing benzimidazole and isoxazole derivatives, challenges such as drug resistance, limited selectivity, and adverse effects necessitate the design of novel analogs with improved pharmacological profiles. The emergence of resistant microbial strains and complex diseases like cancer and neurodegenerative disorders demands the continuous development of structurally diverse and multifunctional compounds [24].

Modifying the core heterocyclic framework through rational design, bioisosteric replacement, and hybridization strategies offers an effective approach to enhancing potency, selectivity, and metabolic stability. Advancements in computational modeling and green synthesis have facilitated the rapid generation of novel derivatives with optimized properties. The pursuit of new benzimidazole and isoxazole analogs thus remains crucial for expanding the therapeutic landscape and addressing unmet clinical needs in modern drug discovery.

2. OVERVIEW OF BENZIMIDAZOLE AND ISOXAZOLE DERIVATIVES:

Benzimidazole and isoxazole derivatives are prominent heterocyclic frameworks exhibiting extensive pharmacological activities. Their structural diversity, electronic adaptability, and ease of functionalization make them versatile scaffolds in medicinal chemistry. These heterocycles continue to play a vital role in developing novel therapeutic agents with enhanced potency and selectivity.

2.1 Chemical Structure and Reactivity:

Benzimidazole and isoxazole exhibit distinct aromatic characteristics and heteroatom arrangements that define their reactivity and biological behavior. Benzimidazole possesses a fused benzene–imidazole ring system with two nitrogen atoms that enable hydrogen bonding and electrophilic substitution, primarily at the C2 position. Isoxazole, a five-membered ring containing adjacent nitrogen and oxygen atoms, exhibits electron delocalization, resulting in stability and resonance. Reactivity in isoxazoles typically occurs at the 3- and 5-positions, influencing substitution reactions. Their electronic versatility and ability to undergo diverse chemical transformations make both scaffolds ideal candidates for drug design and development[25, 26].

2.1.1 Basic Skeleton and Substitution Patterns:

The benzimidazole nucleus consists of a bicyclic system formed by the fusion of a benzene ring with an imidazole ring, yielding a planar, aromatic framework. The nitrogen atoms at positions 1 and 3 provide hydrogen-bonding potential, while the C2 carbon remains the most reactive site for substitution, enabling the introduction of various functional groups to modulate activity. Substituents at positions 5, 6, and 7 on the benzene ring influence lipophilicity and receptor binding[27, 28].

The isoxazole ring, comprising adjacent oxygen and nitrogen atoms, demonstrates aromatic stability and specific substitution at the 3- and 5-positions. These substitution sites dictate electronic distribution, affecting interactions with biological targets. Both frameworks tolerate a wide range of substituents, such as alkyl, halogen, nitro, or amino groups, allowing precise tuning of biological activity and physicochemical properties. This structural flexibility contributes significantly to their therapeutic diversity[29]. Figure **1** summarizes the chemical structures of benzimidazole and Figure **2** summarizes the chemical structures of isoxazole.



1*H*-benzo[*d*]imidazole

Figure 1. Chemical Structures of Benzimidazole



isoxazole

Figure 2. Chemical Structures of Isoxazole

2.1.2 Electronic and Steric Effects on Activity:

Electronic and steric factors play crucial roles in determining the biological activity of benzimidazole and isoxazole derivatives. Electron-donating groups (such as –OH, $–OCH_3$, or $–NH_2$) enhance electron density within the heterocyclic system, increasing binding affinity and bioavailability, while electron-withdrawing groups (such as $–NO_2$ or –Cl) can improve metabolic stability and lipophilicity. In benzimidazoles, substitution at the C2 position significantly alters π-electron distribution and influences receptor interactions. In isoxazoles, substitution at the 3- and 5-positions modulates dipole moments and overall reactivity. Steric hindrance from bulky groups affects molecular conformation and the accessibility of active sites, which may either enhance or reduce biological efficacy. The interplay between these effects allows medicinal chemists to fine-tune drug potency, selectivity, and pharmacokinetic profiles, making both heterocyclic systems highly adaptable for rational drug design [30-32].

2.2 Synthetic Approaches:

Multiple synthetic strategies have been developed to construct benzimidazole and isoxazole derivatives efficiently. Traditional methods, green chemistry approaches, and advanced catalytic techniques have enhanced reaction yields and reduced environmental impact. Modern innovations now focus on sustainable, high-throughput, and nanocatalytic synthesis for precision drug discovery [33]. Figure **3** shows the synthetic routes for benzimidazole derivatives and figure **4** summarizes the synthetic pathways for isoxazole derivatives.



Figure 3. Schematic Representation of Synthetic Routes for Benzimidazole Derivatives



Figure 4. Representative Synthetic Pathways for Isoxazole Derivatives

2.2.1 Classical Methods of Synthesis

Classical synthesis of benzimidazole derivatives often involves the condensation of o-phenylenediamine with carboxylic acids, aldehydes, or ketones. This Phillips-Ladenburg reaction, reported in the late 19th century, uses acidic conditions and heat to facilitate cyclization, yielding benzimidazoles in moderate yields.

Alternate pathways include the Weidenhagen method, reacting o-phenylenediamine with aldehydes/ketones at elevated temperatures, as well as acid-catalyzed rearrangement processes[34].

Isoxazole derivatives are traditionally synthesized through 1,3-dipolar cycloaddition reactions between nitrile oxides and alkynes, first described by Claisen in 1903. Other classic methods include condensation of nitroacetic esters with dipolarophiles, or oximation of propargylaldehyde acetals. The use of hydroxylamine with β-diketones or aldehydes/alkynes is common, and these methods remain staples in heterocyclic chemistry for building isoxazole rings[35].

2.2.2 Green and Eco-friendly Synthetic Routes:

Green synthetic approaches for benzimidazole derivatives often utilize solvent-free conditions, water as a reaction medium, or benign catalysts like zinc acetate, copper nanoparticles, zinc triflate, and ammonium chloride. Several methods employ recyclable catalysts and green solvents like PEG400 to minimize environmental impact and waste. One-pot reactions of o-phenylenediamine with aldehydes in ethanol or water at moderate temperatures and using eco-friendly catalysts yield good results with high atom economy[36-37].

Eco-friendly synthesis of isoxazole derivatives commonly utilizes solvent-free cycloadditions, microwave-assisted reactions, or water/ethanol as sustainable solvents, often catalyzed by reusable nanomaterials. These processes typically avoid hazardous reagents, generate fewer byproducts, and offer reduced energy consumption, aligning with core green chemistry principles. Green methods for these heterocycles reduce waste and enhance efficiency, contributing to more sustainable medicinal chemistry[38].

2.2.3 Microwave-assisted and Solvent-free Synthesis:

Microwave-assisted synthesis enables faster and higher-yielding preparation of benzimidazole derivatives, often using o-phenylenediamine and aldehydes with oxidants like DDQ under microwave irradiation. This approach dramatically reduces reaction times from hours to minutes, enhances product purity, and often results in excellent yields under mild conditions. Solvent-free methods, sometimes performed in combination with microwave heating, further improve eco-friendliness by eliminating harmful solvents, streamlining work-up, and reducing waste[39].

Isoxazole derivatives can also be synthesized using microwave-assisted cycloadditions between nitrile oxides and alkynes without solvents, as well as condensation reactions with hydroxylamine derivatives under solvent-free conditions. These strategies avoid hazardous reagents and minimize byproducts, supporting green chemistry principles and offering efficient, scalable routes for heterocyclic synthesis. This combination of microwave technology and solvent-free procedures represents a significant advancement in sustainable organic synthesis[40].

2.2.4 Catalytic and Nanocatalytic Strategies:

Catalytic strategies for benzimidazole synthesis often involve transition metal catalysts such as iron(III) porphyrin, cobalt nanocomposites, copper oxide nanoparticles, and nickel-decorated SBA-15 nanocomposites. These catalysts promote efficient one-pot, multicomponent reactions of o-phenylenediamines with aldehydes or other precursors under mild, eco-friendly conditions, yielding benzimidazole derivatives with high purity and yield. Nanocatalysts offer advantages including high surface area, reusability, and enhanced activity, making them valuable for sustainable synthesis processes. For example, cobalt and copper nanoparticles have been reported to catalyze benzimidazole formation with good functional group tolerance and catalyst recyclability [41, 42].

For isoxazole derivatives, nanocatalysts such as metal oxide nanoparticles and supported catalysts facilitate cycloaddition and condensation reactions efficiently. These catalytic systems minimize reaction time and energy use while enhancing selectivity and yields, thus exemplifying green chemistry principles in heterocycle synthesis. Catalytic and nanocatalytic methods provide practical, efficient, and environmentally friendlier routes for synthesizing benzimidazole and isoxazole derivatives [43, 44].

2.2.5 Recent Synthetic Advancements:

Recent synthetic advancements from 2020–2025 for benzimidazole derivatives focus heavily on sustainability, efficiency, and broadening molecular diversity. Novel acid-, ester-, ortho-ester-, nitrile-, acid-chloride-, and orthoformate-based building blocks have enabled the rapid synthesis of structurally diverse benzimidazole compounds with enhanced bioactivities. Multi-step sequences have been streamlined through one-pot and multicomponent strategies, including the Mizoroki–Heck reaction for new ligands, as well as metal complex formation (e.g., using $ZnCl_2$ or $CoCl_2$) for potent anticancer agents. Advances in catalytic and nanocatalytic protocols using cobalt, copper, gold, and iron nanoparticles now provide higher selectivity, yields, and functional group tolerance under mild and water-based conditions.

Metal-free approaches, such as microwave-assisted cyclization and photocatalysis using visible light, offer sustainable alternatives by reducing the need for toxic and expensive transition metals[45, 46].

Green approaches have evolved with eco-friendly initiators, deep eutectic solvents, and water, and have even incorporated plant extracts as catalysts, further lowering toxicity and environmental impact. Transitioning to microwave irradiation and solvent-free procedures has significantly decreased reaction times and improved atom economy. Metal-free strategies yield compounds rapidly at ambient or mild temperatures, aligning well with pharmaceutical standards for purity and safety. The combination of these methods has paved the way for fast, resource-efficient access to complex benzimidazole scaffolds for medicinal research[47, 48].

In parallel, recent advances in isoxazole derivative synthesis focus on cycloadditions and condensations using sustainable solvents, microwave technology, and metal nanoparticle catalysis. Selective, high-yielding, and scalable processes have emerged, avoiding hazardous reagents and maximizing efficiency. Both microwave-assisted and nanocatalytic techniques are especially prominent, allowing for the direct synthesis of highly functionalized isoxazole rings within minutes and with minimal waste. Collectively, these innovations support modern medicinal chemistry by providing cleaner, faster, and broader synthetic access to benzimidazole and isoxazole scaffolds[49, 50].

2.3 Structure–Activity Relationship (SAR)

The structure–activity relationship (SAR) of benzimidazole and isoxazole derivatives reveals how structural modifications influence pharmacological potency and selectivity. Substituent type, position, and electronic properties play critical roles in determining receptor affinity and therapeutic outcomes. Understanding these relationships guides rational drug design and optimization of lead compounds.

2.3.1 Key Pharmacophoric Modifications:

Pharmacophoric modifications in benzimidazole and isoxazole derivatives aim to enhance biological activity, target specificity, and pharmacokinetic properties. In benzimidazoles, substitution at the C2 position with alkyl, aryl, or heteroaryl groups significantly increases antimicrobial, anticancer, and anthelmintic activities, while halogen or nitro groups at C5–C6 positions improve lipophilicity and enzyme binding. Incorporating electron-donating groups enhances receptor interaction via hydrogen bonding and π–π stacking. For isoxazoles, substitutions at the 3- and 5-positions are vital, influencing molecular polarity and bioavailability. Hybridization of benzimidazole or isoxazole cores with pharmacophoric moieties like sulfonamides, carboxamides, or azoles leads to multifunctional compounds with synergistic actions. Such strategic modifications optimize drug–target interactions, reduce toxicity, and expand therapeutic versatility, establishing these scaffolds as adaptable pharmacophores in modern medicinal chemistry[51-53].

2.3.2 Substituent Effects on Bioactivity:

The nature and position of substituents profoundly affect the biological activity of benzimidazole and isoxazole derivatives. Electron-donating groups (e.g., $–OH$, $–OCH_3$, $–NH_2$) generally increase electron density, enhancing hydrogen-bonding interactions with enzyme active sites and improving antimicrobial or antioxidant activity. Conversely, electron-withdrawing groups (e.g., $–NO_2$, $–Cl$, $–CF_3$) enhance lipophilicity and membrane permeability, often boosting anticancer and anti-inflammatory potency. In benzimidazole derivatives, bulky aromatic substituents at C2 enhance π–π stacking with DNA bases, increasing cytotoxic efficacy, while halogenation improves metabolic stability. For isoxazole derivatives, substituents at C3 and C5 modulate dipole moments, affecting receptor binding and selectivity. The combined influence of steric, electronic, and hydrophobic factors determines pharmacological efficiency, guiding medicinal chemists in designing potent, selective, and safe heterocyclic drugs[54-56].

2.3.3 Comparative SAR of Benzimidazole vs. Isoxazole Derivatives:

Benzimidazole derivatives typically show enhanced anti-inflammatory, antimicrobial, and antioxidant activity when electron-withdrawing or lipophilic groups are incorporated at specific positions. For instance, substitution at R^5^ with hydrophilic or methoxy groups favors COX-2 and 5-lipoxygenase inhibition, while lipophilic moieties boost COX-1 selectivity. The presence of cyano, carboxyl, or sulfonic acid groups at the benzimidazole nucleus influences antioxidant activity, with cyano/carboxyl enhancing potency and sulfonic groups diminishing it. Structural modifications, such as halogenation of aniline or Mannich-base formation, also benefit anti-inflammatory and analgesic properties by altering the electronic environment of the core scaffold[57, 58].

Isoxazole derivatives, in contrast, rely heavily on the nature and position of substituents for potency across antimicrobial, antitubercular, antifungal, and anti-inflammatory activities. SAR data show that electron-withdrawing groups on the isoxazole ring enhance anti-inflammatory effects, whereas unsubstituted benzene contributes to strong antibacterial activity. Certain allyl and aryl substitutions at the C5 position of the benzene or isoxazole ring improve nitric oxide inhibition and anti-inflammatory action, with the overall potency sometimes surpassing related heterocycles such as pyrazoles. Recent dual hybrid molecules combining both scaffolds display synergistic bioactivity, especially against microbes and cancer cell lines [59, 60].

Comparatively, benzimidazole derivatives excel in enzyme inhibition and anti-inflammatory action when appropriately substituted, while isoxazole derivatives with large or electron-withdrawing substituents often achieve higher antibacterial and antitubercular efficacy. SAR optimization in both scaffolds leverages electron-withdrawing effects, but the positions and core modification strategies differ, reflecting their distinct mechanisms of action and therapeutic applications[61, 62]. The comparison of Synthetic Strategies for Benzimidazole and Isoxazole Derivatives are summarized in table **1**.

Table 1. Comparison of Synthetic Strategies for Benzimidazole and Isoxazole Derivatives

Aspect	Benzimidazole Derivatives	Isoxazole Derivatives	Remarks / Advantages
Classical Synthesis Route	Condensation of *o*-phenylenediamine with carboxylic acids, aldehydes, or their derivatives under acidic conditions.	Cyclocondensation of β-diketones or β-ketoesters with hydroxylamine hydrochloride in ethanol or glacial acetic acid.	Straightforward methods but involve long reaction times and moderate yields [63].
Catalytic Methods	Metal-catalyzed (Cu, Fe, Pd) oxidative coupling or cyclization using hydrogen peroxide or TBHP.	Metal-catalyzed oxidative cyclization or N–O bond formation using Cu(II) or Fe(III) catalysts.	Enhances selectivity and reaction efficiency; reduces byproducts [64].
Microwave-Assisted Synthesis	Rapid cyclization of *o*-phenylenediamine with aldehydes or acids in solvent-free conditions.	Microwave-assisted condensation of β-diketones and hydroxylamine; often solvent-free.	Shorter reaction time, higher yield, and environmentally benign [65].
Green Chemistry Approach	Solvent-free, ultrasound-assisted, or ionic liquid–mediated synthesis; use of natural catalysts (e.g., citric acid).	Aqueous or ethanol-based synthesis using bio-catalysts or green solvents; lemon juice or PEG-based media.	Eco-friendly, energy-efficient, and sustainable approaches gaining importance [66].
Nanocatalytic Strategies	Utilization of metal oxide nanoparticles (ZnO, TiO_2, CuO) for enhanced cyclization efficiency.	Application of nanocatalysts like Fe_3O_4 or Ag nanoparticles in heterocyclization reactions.	Increases surface area, accelerates reaction kinetics, and allows catalyst reusability [67].
Recent Synthetic Trends (2020–2025)	Development of benzimidazole–hybrid scaffolds (benzimidazole–triazole, benzimidazole–quinoline).	Focus on hybrid systems such as isoxazole–thiadiazole and isoxazole–quinazolinone derivatives.	Hybridization enhances biological activity and target selectivity [68].

2.4 Computational and In-silico Design:

Computational and in-silico techniques play a vital role in accelerating the discovery of benzimidazole and isoxazole derivatives. These methods enable prediction of molecular interactions, activity, and pharmacokinetic properties prior to synthesis. Tools such as molecular docking, QSAR, and predictive modeling help identify potent lead compounds efficiently.

2.4.1 Molecular Docking and QSAR Studies:

Molecular docking and Quantitative Structure–Activity Relationship (QSAR) studies are essential computational approaches for understanding the interaction of benzimidazole and isoxazole derivatives with biological targets. Molecular docking simulates ligand–receptor binding to predict binding affinities, key interactions, and possible conformations within active sites. This helps in identifying the most promising analogs for further synthesis and biological evaluation. QSAR modeling, on the other hand, quantitatively correlates molecular descriptors such as hydrophobicity, electronic distribution, and steric factors with biological activity. For benzimidazole derivatives, QSAR has highlighted the importance of electron-withdrawing substituents at the C2 position for improved enzyme inhibition, while in isoxazoles, lipophilic substituents at positions 3 and 5 enhance anti-inflammatory activity. Together, these computational tools provide a rational basis for designing derivatives with optimal pharmacodynamic and pharmacokinetic properties [69, 70].

2.4.2 Predictive Modeling for Activity Optimization:

Predictive modeling integrates computational algorithms and artificial intelligence to forecast the biological performance of new benzimidazole and isoxazole derivatives before laboratory synthesis. These models utilize machine learning, pharmacophore mapping, and molecular dynamics simulations to predict binding affinity, selectivity, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles. By analyzing large datasets of known compounds, predictive tools can identify structural motifs responsible for enhanced bioactivity. For instance, models may suggest substituent patterns or hybrid structures that improve drug–target complementarity or reduce off-target effects. In recent years, AI-assisted virtual screening has accelerated hit identification, allowing chemists to focus only on high-probability candidates. Consequently, predictive modeling not only reduces time and cost in drug discovery but also enhances precision in designing safe and effective benzimidazole and isoxazole-based therapeutics [71-73].

3. Biological Properties Of Benzimidazole Derivatives:

Benzimidazole derivatives display a broad spectrum of biological activities due to their versatile chemical structure and strong interaction with biomolecular targets. Their derivatives have been extensively studied for antimicrobial, antiviral, anticancer, anti-inflammatory, and antioxidant potential. These pharmacological effects make benzimidazoles valuable frameworks in modern therapeutic development.

3.1 General Biological Activities:

The biological versatility of benzimidazole derivatives arises from their ability to interact with enzymes, DNA, and receptor proteins through hydrogen bonding and π–π interactions. Structural modifications at the C2 and C5 positions enhance target specificity and potency. Consequently, these compounds exhibit activity against diverse pathogens and disease pathways.

3.1.1 Antiviral Activity

Lassa virus (LASV) is the causative agent of Lassa fever, a severe viral hemorrhagic disease with high mortality and no currently approved specific treatments, highlighting the need for novel therapeutics. Recent studies have shown that benzimidazole-based molecules targeting the arenavirus envelope glycoprotein complex (GPC) represent a promising antiviral strategy. In this study, two series of benzimidazole analogs were synthesized and evaluated as LASV entry inhibitors using lentiviral pseudotypes expressing LASV GPC. Surface plasmon resonance (SPR) analysis confirmed strong binding interactions. Among all synthesized compounds, 7d−Z, 7h−Z, 13c, 13d, and 13f demonstrated potent antiviral efficacy, with IC50 values between 7.58–15.46 nM and selectivity index values above 1251. Notably, compound 7h−Z exhibited exceptional activity (IC50 = 7.58 nM; SI = 2496) and can be considered a promising lead candidate. Structure–activity analysis suggested that lipophilic, bulkier substituents significantly enhance antiviral potency and safety, providing direction for future optimization [74].

A study aimed to design and synthesize novel enaminonitrile derivatives originating from 2-aminobenzimidazole and further convert them into various heterocyclic scaffolds, followed by biological evaluation. The key intermediate N-(1H-benzo[d]imidazol-2-yl)carbonohydrazonoyl dicyanide (2) was obtained via coupling of diazotized 2-aminobenzimidazole with malononitrile. Compound 2 reacted with several secondary amines to furnish acrylonitrile derivatives (3–8). It also showed versatile reactivity toward hydrazine hydrate, malononitrile, triethyl orthoformate, acid anhydrides, and cyclization reagents, yielding a diverse series of benzimidazole-based heterocycles (9–26). Biological evaluations revealed that compound 14 exhibited the highest ABTS antioxidant and pronounced antitumor activity. Cytotoxicity screening on VERO, MCF-7, WI-38, and HepG2 cell lines indicated selective and strong activity for multiple derivatives, especially 9, 11, 14, 15, 16, 22, 23, 24, and 25. Molecular docking demonstrated that compound 24 showed a very promising binding score (−8.12), stabilized through hydrogen bond interactions with Arg184 and Lys179, suggesting strong therapeutic potential [75].

In a study, 26 benzimidazole derivatives containing an alkyl linker at the N-1 position were synthesized and structurally confirmed using spectral techniques. Their anti-HIV potential was evaluated using the HIV-1 reverse transcriptase RNA-dependent DNA polymerase assay. Compounds 43, 45, 50 and 51 demonstrated notable HIV-1 RT inhibitory activity, although less potent compared to efavirenz, while the remaining derivatives showed weak activity. Antimicrobial evaluation revealed that most compounds exhibited strong antibacterial activity against Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis) and several Gram-negative species (E. coli, S. typhi, K. pneumoniae, P. aeruginosa), with compounds 37, 43, 45, 50 and 51 being the most active, though less potent than ciprofloxacin. For antifungal activity, nearly all derivatives showed comparable or superior activity to fluconazole except 34, 39, 42, 47 and 48, which showed moderate effects. SAR, ADME, and toxicity modeling established relationships between biological activity and electronic/physicochemical parameters of the synthesized molecules [76].

3.1.2 Antifungal Activitiy

In a work, three novel series of benzimidazole-based derivatives containing hydrazone, 1,2,4-triazole and 1,3,4-oxadiazole motifs (1–3, 4a–j, 6a–c and 7) were designed, synthesized and evaluated for antimicrobial activities. The structures of the synthesized compounds were confirmed through IR, ^1H NMR, ^13C NMR and elemental analyses. Compounds 3, 4a, 4e and 4f showed strong antifungal activity against Candida albicans and C. neoformans var. grubii, with MIC values between 4–16 µg/mL, without showing cytotoxicity toward red blood cells or human embryonic kidney cells up to 32 µg/mL. Mechanistic studies using sterol quantitation revealed that compound 4e demonstrated potent inhibition of lanosterol 14α-demethylase (CYP51) (IC50 = 0.19 µg/mL), outperforming fluconazole (IC50 = 0.62 µg/mL). Additionally, compounds 4d and 4f exhibited mild to moderate antibacterial activity. Molecular docking of compound 4e within CYP51 validated its binding interactions, while in-silico ADME predictions supported good drug-like properties [77].

In a study, a series of benzimidazole derivatives bearing thioether and carbamate moieties have been synthesized and evaluated for their in vitro antifungal activity against Cytospora mandshurica, Thanatephorus cucumeris, Botrytis cinerea, Verticillium daliae, Phytophthora infestans, and Gibberella zeae by the mycelium growth rate method. The result of bioassay demonstrated that most of the compounds had certain antifungal activity. Especially, compound E11 revealed better antifungal activity against Verticillium daliae and Phytophthora infestans at 50 µg/mL, with the inhibition rates of 70% and 75%, respectively, than those of albendazole (38% and 61%, respectively). To the best of our knowledge, it is the first study on the synthesis and antifungal activity of benzimidazole derivatives containing thioether and carbamate moieties [78].

Two series of N-substituted heteroaromatic compounds structurally related to clotrimazole were synthesized. In the first series (c), the ortho-chlorotrityl moiety was replaced by trityl, mono- or dimethoxy-trityl groups, while in the second series (d), the imidazole ring was replaced by benzimidazole. All compounds were structurally confirmed by spectrophotometric characterization. Molecular docking against MT-CYP51 (PDB: 1E9X) using AutoDock demonstrated strong affinity comparable to clotrimazole. Antifungal activity was evaluated against Trichophyton mentagrophytes, Microsporum gypseum and Candida albicans using PDA medium and agar dilution assay. Compounds 1c, 6d and 2c exhibited 100%, 90% and 70% inhibition respectively. Further evaluation against T. rubrum, M. canis and E. floccosum revealed that 1c and 6d exhibited 100% activity, while 2c and 3c showed >75% inhibition. The most active analogues (1c, 2c and 6d) were additionally tested in RPMI-1640 medium and showed favorable antifungal activity comparable to clotrimazole [79].

3.1.3 Antibacterial Activity:

Two groups of benzimidazole derivatives were synthesized from 5(6)-substituted 2-mercaptobenzimidazole-thiols, and their antioxidant activities were evaluated using the TBA–MDA assay. In the 1,3-disubstituted benzimidazol-2-imine series, ethyl [3-(2-ethoxy-2-oxoethyl)-2-imino-5-benzoyl-2,3-dihydro-1H-benzimdazol-1-yl]acetate (compound 12) showed the highest lipid peroxidation inhibition (74.04%, IC50 = 141.89 µg/mL). In the thiazolo[3,2-a]benzimidazolone series, compound 17 showed the strongest inhibition (90.76%, IC50 = 53.70 µg/mL). To investigate radical scavenging behavior, the most active compounds in each subgroup were optimized at the B3LYP/6-311++G** level and bond dissociation enthalpies were calculated to propose HAT and SET antioxidant mechanisms. Antibacterial activity was assessed against Bacillus subtilis, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Salmonella abony. Compound 14 (1,3-diphenylpropyl-5-methyl-1,3-dihydro-2H-benzimidazol-2-imine) exhibited potent activity with MIC values from 0.016 to 0.50 mg/mL. However, the thiazolobenzimidazolone derivatives showed no antibacterial activity [80].

Benzimidazole derivatives are of wide interest because of their presence in numerous categories of medicinal drugs; such as anticancer, anticoagulants, antihypertensives, anti-inflammatory, antimicrobials, antiparasites, antivirals, antioxidants, immunomodulators, proton pump inhibitors, hormone modulators, CNS stimulants as well as depressants, lipid level modulators, antidiabetics, etc., makes it a moiety of great importance in medicinal chemistry. Because of this great importance, it attracts the researchers to synthesize more effective benzimidazole derivatives for several biological activity screening. Many reviews and mini reviews on importance of benzimidazole nucleus for medicinal purpose are present [81].

A new series of benzimidazole derivatives (1-15) containing 1,2,4-triazole, 1,3,4-thiadiazole, 1,3,4-oxadiazole, and thiazolidinon rings have been synthesized. All new synthesized benzimidazole compounds were confirmed by 1H NMR, 13C NMR spectra, and LC-MS, and they were examined for their antioxidant and antimicrobial activities. Compounds 7 and 1 showed the highest and the lowest antioxidant activities, respectively. The lowest minimum inhibition concentration value found in compound 5 against Enterobacter aerogenes [82].

3.1.4 Anti-inflammatory Activity:

Hyper-inflammation significantly worsens the outcomes of many communicable and non-communicable diseases, making anti-inflammatory agents clinically valuable across therapeutic areas.

Benzimidazole is a well-established privileged heterocyclic scaffold and serves as the backbone of several approved drugs. In this study, three new benzimidazole derivatives (MBPHYD, MBNHYD and MBHYDX) were synthesized, purified and characterized, and their safety was assessed. All compounds were non-toxic in vitro at 100 µM (24 h against 3000 Vero cells/well), and in vivo at 100 mg/kg in female Wistar rats (no mortality up to 48 h). Among these, MBPHYD and MBNHYD demonstrated significant anti-inflammatory activity. Computational drug-likeness screening supported favorable pharmacokinetic profiles, predicted good oral bioavailability and indicated no toxicity alerts. These findings suggest that the newly developed benzimidazole derivatives, especially MBPHYD and MBNHYD, have promising anti-inflammatory potential and warrant further optimization and detailed in vivo pharmacological evaluation for potential therapeutic application [83].

Many currently available anti-inflammatory drugs are losing therapeutic relevance due to safety concerns, adverse effects, and limitations in long-term use. Therefore, significant efforts in recent years have focused on discovering new anti-inflammatory agents with improved efficacy and safety profiles. Heterocyclic scaffolds, especially benzimidazoles, have gained major attention because of their structural similarity to natural biomolecules and their well-established pharmacological versatility. Benzimidazole-based compounds demonstrate anti-inflammatory activity by modulating multiple biological targets, including TRPV1, cannabinoid receptors, bradykinin receptors, cytokines, 5-lipoxygenase activating protein and cyclooxygenase enzymes. Structure–activity relationship studies confirm that substituent type and position on the benzimidazole ring strongly influence biological activity. Substitutions at N1, C2, C5 and C6 positions are crucial for regulating anti-inflammatory potency. For instance, C2 anacardic acid derivatives show COX-2 inhibition, while 5-carboxamide or sulfonyl substitutions exhibit cannabinoid receptor antagonism. Overall, SAR insights provide valuable guidance for designing next-generation benzimidazole derivatives as safer and more effective anti-inflammatory agents [84].

Many nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both COX-1 and COX-2, but selective COX-2 inhibition is preferred due to its key role in disease-associated inflammation. Apart from COX enzymes, other biological targets such as Aldose Reductase, Aldo-ketoreductase 1-C2 (AKR1C2) and Phospholipase A2 also contribute to inflammatory disorders. In this study, a series of 2-substituted benzimidazole derivatives was synthesized and evaluated for anti-inflammatory activity through in vitro assays and in vivo models. Molecular docking investigations were performed to determine the binding interactions of these derivatives with COX enzymes and other relevant targets linked to NSAID action. Compounds B2, B4, B7 and B8 displayed IC50 values lower than ibuprofen in the Luminol-enhanced chemiluminescence assay. Their efficacy was further confirmed in a carrageenan-induced mice paw edema model, showing anti-inflammatory activity comparable to diclofenac sodium. Overall, these results indicate that the synthesized benzimidazole derivatives may serve as promising multi-target anti-inflammatory candidates [85].

3.1.5 Synergistic Effects:

A series of new benzimidazole derivatives was synthesized and characterized by IR, 1H NMR, 13C NMR, MS, and HRMS spectra. All the new compounds were screened for their antimicrobial activities in vitro by a twofold serial dilution technique. The bioactive evaluation showed that 3,5-bis(trifluoromethyl)phenyl benzimidazoles were comparably or even more strongly antibacterial and antifungal than the reference drugs Chloromycin, Norfloxacin, and Fluconazole. The combination of 2,4-difluorobenzyl benzimidazole derivative 5l and its hydrochloride 7 respectively with the antibacterials Chloromycin, Norfloxacin, and the antifungal Fluconazole was more sensitive to methicillin-resistant MRSA and Fluconazole-insensitive A. flavus. In addition, the interaction of compound 5l with calf thymus DNA demonstrated that this compound could effectively intercalate into DNA to form a compound 5l-DNA complex that might block DNA replication and thereby exert good antimicrobial activity[86].

A series of 2-chloro benzimidazole derivatives was synthesized and evaluated for antibacterial activity. Several compounds, particularly 2d, 2e, 3a, 3b, 3c, 4d, and 4e, exhibited potent activity against Bacillus cereus, Staphylococcus aureus and Pseudomonas aeruginosa (MIC: 6.2 µg/mL), along with excellent inhibition of Escherichia coli (MIC: 3.1 µg/mL). Notably, compounds 3d and 3e demonstrated superior antibacterial activity (MIC: 3.1 µg/mL) compared to standard drugs chloramphenicol and cycloheximide, against both Gram-positive and Gram-negative bacteria. These compounds also performed better than paromomycin against B. cereus and P. aeruginosa and showed comparable activity against S. aureus and E. coli. Fractional inhibitory concentration (FIC) studies indicated synergistic effects, reducing MIC values up to 1/8th–1/33rd of initial levels. In vitro cytotoxicity results revealed lower toxicity of these benzimidazole derivatives toward PBM, CEM, and Vero cell lines. Docking, molecular dynamics simulations, and in silico ADMET studies further supported their promising drug-like characteristics and potential antibacterial mechanism via interaction with the eubacterial ribosomal decoding A-site [87].

3.1.6 Antioxidant Activity:

A number of benzimidazole compounds namely, N-(4-(1H-benzimidazol-2-yl)phenyl)-4-(1H-benzimidazol-2- yl)-benzamide derivatives (8-10) and N-(3- or 4-(1H-benzimidazol-2-yl)phenyl)-2-phenyl-1H-benzimidazole-5- carboxamide derivatives (18-21) were synthesized and antibacterial and antioxidant activities were evaluated. Antibacterial activities of 9, 10, 18, and 20 against MRSA-isolate are equal to ampicillin. Compounds 18, 19, and 21 displayed better antifungal activities against Candida albicans. Antioxidant properties were evaluated by several methods, such as inhibition of lipid peroxidation, superoxide anion production, and DPPH stable free radical, and also their effects on hepatic cytochrome P450 (CYP) dependent ethoxyresorufin O-deethylase (EROD) enzyme were determined in rats in vitro. Compounds 18 and 20 had strong scavenger effect on superoxide anion (90%, and 99%, respectively) at 10-3 M concentration. Compound 19 showed significant inhibition on EROD activity with 98%, which is better than that of caffeine being a specific inhibitor of EROD activity (85%) [88].

Novel benzimidazole–1,3,4-oxadiazole derivatives were synthesized and evaluated for antioxidant activity using the DPPH radical scavenging assay. Benzimidazole scaffolds are well known for exhibiting diverse pharmacological properties, and incorporation of five-membered heterocyclic systems such as 1,3,4-oxadiazole can further enhance biological potential. In this study, newly designed benzimidazole derivatives were characterized using FTIR and ^1H NMR spectral techniques. The antioxidant evaluation revealed that these compounds possessed significant free-radical scavenging properties. Docking analysis showed that compounds 1A, 2A, and 3A exhibited high Glide scores of −7.575, −6.932, and −6.911 kcal/mol, respectively, outperforming the standards propyl gallate and ascorbic acid (−4.757 and −4.50 kcal/mol). Among the tested molecules, compound 2A showed the most promising antioxidant effect, with an IC_{50} of 53.00 ± 1.31 µg/mL, compared to ascorbic acid (IC_{50} = 11.51 ± 0.31 µg/mL). These findings suggest benzimidazole–oxadiazole hybrids as promising scaffolds for developing potent antioxidant agents [89].

A novel series of 2-substituted benzimidazole and benzoxazole derivatives was synthesized by coupling N-methyl-o-phenylenediamine or 2-aminophenol with aromatic aldehydes and acids using polyphosphoric acid as a highly effective catalyst and solvent. This conventional approach enabled short reaction times with excellent yields. The resulting derivatives were evaluated for antimicrobial and antioxidant potential and demonstrated good-to-excellent activity when compared with standard reference drugs. Molecular docking studies against microbial DNA gyrase provided mechanistic insights, indicating that these compounds show strong binding affinity and favourable thermodynamic interactions, supporting their observed antimicrobial efficacy. In addition, ADME prediction revealed that most derivatives possess promising drug-like characteristics, with acceptable absorption, distribution, metabolism, and excretion features. Based on these experimental and computational findings, the synthesized benzimidazole and benzoxazole derivatives appear to be strong candidates for further development as potential antimicrobial and antioxidant therapeutic agents [90].

3.1.7 Anti-cancer Activity:

Aresearch deals with an efficient green chemistry for synthesizing a series of Schiff bases 3a-m incorporating 4-1H-benzo[d] imidazole moiety, by microwave technique and heating conventional procedures which are used for their preparation. The newly synthesized Schiff bases are obtained by the reaction of 4-(1H-benzo[d]imidazol-2yl) aniline 1 with a series of different aromatic aldehydes 2a-m. This work aims to make a comparison between conventional and microwave irradiation methods. The design of selected newly Schiff bases is defined by molecular modeling. The evaluation of anticancer activities of synthesized Schiff bases are investigated against human cancer cell lines; Co rectal cancer cell line HCT116, human liver cancer cell line HepG2 and human ovarian cancer cell line A2780, the results show that compounds 3c,3f,3g have more activity than the comparing drug CK0106023. All the synthesized compounds are characterized by their elemental analysis, IR, H-NMR and Mass spectral studies [91].

Benzimidazole is a bicyclic aromatic heterocycle composed of a benzene ring fused with an imidazole ring, and is recognized as an important pharmacophore in medicinal chemistry. Benzimidazole derivatives exhibit broad therapeutic potential, including analgesic, antifungal, anti-inflammatory, antihypertensive, proton pump inhibitory, antiviral, anti-HIV, and anticancer activities. Recently, the emergence of multidrug resistance in cancer has driven the search for novel chemotherapeutic agents. Target-based drug discovery has become one of the most effective strategies to identify new molecules capable of selectively inhibiting cancer-related pathways. In this context, benzimidazole-based structures have gained significant attention due to their structural flexibility, ease of functional modification, and strong interaction with multiple biological targets. Therefore, the last five years of research focusing on benzimidazole derivatives as anticancer agents has been reviewed and summarized. This review highlights key targets involved in cancer treatment and discusses how structural modifications influence the biological activity of benzimidazole scaffolds [92].

DNA topoisomerase I regulates DNA topological structure in many cellular metabolic processes and is a validated target for the development of antitumor agents. In this work, a series of novel 2-[(5-(4-(5(6)-substituted-1H-benzimidazol-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio]-1-(4-substitutedphenyl)ethan-1-ones (4a–4s) derivatives have been synthesized and evaluated for DNA Topo I inhibition and cytotoxicity. The structures of the compounds (4a–4s) were confirmed by IR, 1H-NMR, 13C-NMR, 2D NMR, and mass spectroscopy. Anticancer activity of these compounds was assessed against two different human cancer cell lines A549 (human lung adenocarcinoma) and HepG2 (human liver cancer cell line), as well as normal mouse embryonic fibroblast cells (NIH3T3). IC50 values of compounds 4a, 4c, and 4f were highest than those exhibited for the reference drug cisplatin. Then, the inhibitory effect of 4a, 4c, and 4f compounds on topoisomerase I enzyme with the relaxation assay was investigated on supercoiled DNA using agarose gel electrophoresis. The Annexin V-FITC assay demonstrated that these compounds induce cell death by apoptosis [93].

3.2 Mechanism of Action:

Benzimidazole derivatives exhibit diverse biological activities through multiple mechanisms involving enzyme inhibition, receptor modulation, DNA intercalation, and protein binding.

3.2.1 Enzyme Inhibition and Receptor Interactions

Benzimidazole compounds act as potent inhibitors of various enzymes and receptors, serving critical roles in anticancer, anti-inflammatory, and antiparasitic therapies. Many function as kinase, topoisomerase, and PARP inhibitors, binding to active sites via hydrogen bonding, van der Waals, and hydrophobic interactions, disrupting signaling pathways vital for tumor growth and cell division. Additionally, derivatives such as mebendazole and albendazole target β-tubulin, preventing microtubule assembly, thereby inhibiting cell division in parasites and cancer cells. Some specialized benzimidazoles interact with androgen and vascular endothelial growth factor receptors, mediating effects through polar, aromatic, and pi–pi stacking interactions [94, 95].

3.2.2 DNA Intercalation and Protein Binding:

Benzimidazole derivatives are known for their DNA intercalation ability, particularly binding to the minor groove at AT-rich sequences. This interaction alters DNA conformation and impedes the function of DNA-binding proteins such as topoisomerases, polymerases, and transcription factors, leading to the inhibition of replication, transcription, and repair. Compounds like Hoechst 33258 serve as illustrative examples, binding DNA to disrupt replication in malignancies. Similarly, metal–benzimidazole complexes can enhance protein–DNA binding, exhibiting stronger effects than free ligands [96, 97]. Figure **5** summarizes the mechanisms of action of benzimidazole derivatives in biological systems.



Figure 5: Mechanisms of Action of Benzimidazole Derivatives in Biological Systems

3.3 Pharmacokinetic and ADMET Considerations:

Benzimidazole derivatives display unique pharmacokinetic (ADME) and toxicity profiles critical for their therapeutic applications.

3.3.1 Absorption, Metabolism, and Excretion Trends:

Benzimidazoles generally have low water solubility, resulting in variable oral bioavailability from 2% to 60%. After oral intake, they undergo first-pass metabolism in the liver, producing both active and inactive metabolites. Many derivatives bind plasma proteins, and their pharmacokinetics can shift from linear to nonlinear at higher doses. Excretion occurs mainly via feces for most benzimidazoles, though some (e.g., albendazole) are excreted in urine as their oxidized sulfoxide or sulfone metabolites. Hepatic metabolism often yields compounds with altered or reduced bioactivity, with enterohepatic recycling further prolonging systemic exposure. Prodrugs and various formulation approaches have recently improved gastrointestinal absorption for newer analogs [98, 99].

3.3.2 Toxicity Profile and Safety Data:

Benzimidazole derivatives are generally characterized by favorable safety margins. Animal studies demonstrate that new compounds often exhibit higher LD_{50} values indicating low acute toxicity compared to reference drugs. Predicted ADMET (absorption, distribution, metabolism, excretion, toxicity) profiles suggest good oral tolerance, minimal interactions with drug transporters like P-glycoprotein, and low predicted mutagenicity or hepatotoxicity for most new benzimidazoles. Nevertheless, some older or less-optimized derivatives may pose hepatotoxicity risks or cause rare allergic reactions, underscoring the need for careful dose optimization and monitoring. Structural modifications and nanocarrier formulations continue to improve safety, efficacy, and pharmacokinetic profiles for clinical and veterinary applications [100]. Table **2** summarizes the selected benzimidazole derivatives and their reported pharmacological activities.

Table 2. Selected Benzimidazole Derivatives and Their Reported Pharmacological Activities

Benzimidazole Derivative / Substitution Pattern	Reported Pharmacological Activity	Probable Mechanism / Biological Target
2-Substituted Benzimidazole with aryl or heteroaryl groups	Antimicrobial (Gram +/– bacteria)	Inhibition of DNA gyrase and topoisomerase IV, interfering with bacterial DNA replication [101].
5-Nitrobenzimidazole derivatives	Antifungal	Inhibition of lanosterol 14α-demethylase (CYP51), blocking ergosterol biosynthesis [102].
2-(Trifluoromethyl)-1H-benzimidazole	Antiviral (HBV, Influenza)	Binding to viral DNA polymerase and neuraminidase, disrupting viral replication [103].
Benzimidazole–Carboxamide hybrids	Anti-inflammatory	Selective inhibition of COX-2 enzyme, reducing prostaglandin synthesis [104].
Benzimidazole–Chalcone conjugates	Antioxidant / Cytoprotective	Radical scavenging via electron transfer and hydrogen donation [105].
Benzimidazole–Thiadiazole hybrids	Anticancer	Induction of mitochondrial apoptosis and cell cycle arrest at G_2/M phase [106].
2-Amino-5-bromobenzimidazole	Anthelmintic	Interaction with β-tubulin, disrupting microtubule formation in parasites [107].
Benzimidazole–Schiff base derivatives	Antimicrobial / Cytotoxic	Binding to bacterial enzymes and Bcl-2 protein, inducing apoptosis [108].
Benzimidazole–Metal complexes (Cu(II), Zn(II))	Anticancer / Antioxidant	Metal-mediated ROS generation and DNA interaction [109].
Benzimidazole–Isoxazole hybrids	Broad-spectrum anti-infective	Dual inhibition of DNA gyrase and COX-2, indicating multi-target activity [110].

4. Biological Properties of Isoxazole Derivatives:

Isoxazole derivatives exhibit diverse biological activities, making them significant in drug discovery. Their core structure enables various pharmacological effects, including antimicrobial, anti-inflammatory, anticancer, and antiviral properties.

4.1 General Biological Activities:

Isoxazole moieties are widely explored due to their broad spectrum of activities. They act as analgesic, anticancer, antimicrobial, antihistaminic, anti-tubercular, immunomodulatory, and antiplatelet agents. Many marketed drugs incorporate isoxazole, demonstrating its essential role in treating multiple diseases. Specific substitutions on the isoxazole ring, such as methyl, methoxy, phenyl, or thiazole groups, often enhance their biological effects and selectivity.

4.1.1 Antiviral Activity:

A series of novel pyrazole-hydrazone derivatives containing an isoxazole moiety were synthesized. Antiviral bioassays indicated that some of the title compounds exhibited better in vivo antiviral activities against tobacco mosaic virus (TMV). In particular, compounds 6a, 6c and 6q exhibited the best curative activity, protection activity, and inactivation activity against TMV, respectively, which were superior to those of Ningnanmycin. This study demonstrated that this series of novel pyrazole-hydrazone derivatives containing an isoxazole amide moiety could effectively control TMV [111].

Amino acid 1092 (AA1092) in the capsid protein of coxsackievirus B3 (CVB3) plays a critical role in susceptibility to capsid-binding antivirals such as pleconaril. While isoleucine at this position supports drug activity, substitutions with leucine or methionine render the virus resistant. In this study, novel analogues with modified central phenoxy groups were synthesized to overcome pleconaril resistance. Specifically, two [(biphenyloxy)propyl]isoxazoles and pleconaril derivatives without methyl substituents in the central ring were prepared using Suzuki coupling and evaluated against pleconaril-resistant CVB3 Nancy strains. Additionally, analogues containing 3-methyl, 3-methoxy, 3-bromo, or 2,3-dimethyl substitutions were examined for activity across CVB variants with different AA1092 residues, other CVB types, and rhinoviruses. The findings highlight that substituent pattern on the core phenoxy ring strongly influences antiviral activity. Remarkably, the 3-methyl and 3-bromo derivatives restored activity against resistant CVB3, and the 3-bromo compound showed broad efficacy across multiple enteroviruses and rhinoviruses [112].

In a study, a series of novel isoxazole-amide derivatives containing an acylhydrazone moiety were synthesized and evaluated for their antiviral activities against tobacco mosaic virus (TMV) and cucumber mosaic virus (CMV). Antiviral bioassays indicated that some of the target compounds exhibited better in vivo antiviral activities against TMV and CMV than those of Ningnanmycin (NNM). Especially, the compound 7t exhibited the best curative, protection, and inactivation activities against TMV and CMV which were superior to those of NNM. Meanwhile, our present work also revealed that compound 7t could enhance the defense-related enzyme activity and increase the chlorophyll content in tobacco leaves to induce resistance and enhance plant tolerance to TMV infection [113].

4.1.2 Anti-inflammatory Activity:

Many Isoxazole derivatives are stated to have good anti-inflammatory activity. Chalcones are prepared by the reaction of aromatic aldehydes with aromatic ketones in aqueous alcoholic alkaline medium. Then these are made to react with hydroxylamine hydrochloride and sodium acetate to prepare isoxazole derivatives. The prepared isoxazole compounds are subjected to inflammatory activity by in-vitro and in-vivo methods. All compounds exhibited anti-inflammatory activity among tested 25 isoxazole derivatives. out of these 25 isoxazole derivatives 7 of them shows significant anti-inflammatory activity [114].

Recent interest in isoxazoles, pyridazines, and pyrimidopyrazines has grown due to their demonstrated anticancer, neuroprotective, analgesic, and anti-inflammatory properties. In this study, novel heterocyclic derivatives incorporating isoxazole, pyridazine, and pyrimidopyrazine frameworks were synthesized using 5,8-alkyl-1,3-dimethyl-5,6-dihydropyrimido[5,6-e]pyrazine-2,4,7-trione (1a,b) as the key starting substrate. The synthetic protocol yielded the target derivatives in moderate to good yields (60–75%) under mild reaction conditions, and their structures were confirmed using IR, 1D/2D NMR, and mass spectrometry. Pharmacological evaluation revealed that the isoxazole derivatives (3a–f) exhibited the strongest in vivo anti-inflammatory and analgesic activities, as demonstrated in carrageenan-induced paw edema, hot-plate, and acetic acid-induced writhing models. In contrast, the pyrimidopyrazine derivatives (4a–f) showed moderate but still noteworthy anti-inflammatory and analgesic effects, comparable to standard references. Overall, this study identifies isoxazole-based analogues as particularly promising scaffolds for future development of potent anti-inflammatory and analgesic drug candidates [115].

Isoxazole is a valuable heterocyclic scaffold with wide biological utility, including anti-inflammatory applications. In a recent investigation, thirteen substituted-isoxazole derivatives (5a–5m) were synthesized and evaluated for their anti-inflammatory potential. Four of these compounds (5c, 5d, 5e, and 5g) were reported as novel molecules. The derivatives were synthesized via cyclization of chalcones with hydroxylamine hydrochloride in ethanol, followed by purification and structural confirmation through FT-IR, ^1H NMR, ^13C NMR, and MS analysis. In vivo evaluation using carrageenan-induced paw edema in rats revealed that compounds 5b, 5c and 5d had the highest anti-inflammatory activity, producing 71–76% edema inhibition within 3 hours with minimal toxicity. Molecular docking studies supported the experimental findings, with compounds 5b, 5c, and 5d showing favourable binding affinity (−8.7 to −8.4 kcal/mol) at the COX-2 active site and stable interactions with key residues such as Cys41, Ala151 and Arg120. Overall, these isoxazole derivatives represent promising leads for further development of safer anti-inflammatory drug candidates [116].

4.1.3 Anti-cancer Activity:

Forskolin C1-isoxazole derivatives (3,5-regioisomers) (11a–e, 14, 15a–h and 15, 16a–g) were synthesized regioselectively by adopting 1,3-dipolar cycloadditions. These derivatives were tested using estrogen receptor positive breast cancer cell lines MCF-7 and BT-474. Majority of the compounds exhibited activity against the p53-positive MCF-7 breast cancer cells but not against the p53-negative BT-474 breast cancer cells. Among forskolin derivatives, compounds 11a, 11c, 14a, 14f, 14g, 14h, 15b, 16g and 17b exhibited higher anti-cancer activity against MCF-7 cell line with an IC50 ≤ 1 µM. The derivative 14f exhibited highest activity in both p53-positive (MCF-7) and p53-negative (BT-474) breast cancer cell lines with an IC50 of 0.5 µM [117].

A recent study reported the rational design, synthesis, and biological evaluation of a new series of phenyl–isoxazole–carboxamide derivatives to explore their antitumor and antioxidant potential. The compounds were screened in vitro against four human cancer cell lines—Hep3B, HepG2, HeLa, and MCF-7—using the MTS cytotoxicity assay, along with Hek293T as a normal cell line reference. Most of the synthesized molecules showed moderate to potent inhibitory activity particularly against Hep3B and MCF-7, except compound 2e which was comparatively weak. Compound 2a exhibited the most notable cytotoxicity against HeLa and Hep3B cancer cells, demonstrating IC_{50} values of 0.91 µM and 8.02 µM, respectively. The overall IC_{50} values of the new agents against Hep3B ranged from 5.96–28.62 µM, while maintaining significantly lower toxicity to normal Hek293T cells compared to doxorubicin. Antioxidant evaluation using the DPPH assay revealed generally weak scavenging activities, although compound 2d displayed moderate potential (IC_{50} = 138.50 µM) relative to Trolox [118].

14 new structures of isoxazole-moiety-containing quinazoline derivatives(3a~3n) were synthesized for the first time and characterized by IR, 1H NMR, 13C NMR, ESI-MS. Subsequently, their in vitro anticancer activity against A549, HCT116 and MCF-7 cell lines was preliminarily evaluated using the MTT method. Among them, most compounds showed good to excellent anticancer activity, especially 3d, 3i, 3k and 3m exhibited the more potent anticancer activity against A549, HCT116 and MCF-7 cell lines, which can be regarded as the promising drug candidates for development of anticancer drugs [119].

4.1.4 Antifungal Activity:

A comprehensive antifungal evaluation was carried out on fifty-three heterocyclic sulphonyl derivatives, including sulphonamides, sulphonyl azides, sulphonohydrazides, and sulphonohydrazones derived mainly from substituted thiophenes, along with a smaller series based on isoxazole, pyrazole, and thiazole scaffolds. The compounds were screened against Mucor mucedo, Septoria nodorum, Trichoderma viride, Chaetomium globosum, and Aspergillus niger. Among these, thiophene-2-sulphonyl derivatives displayed the most potent antifungal profiles at 100 mg/L concentration, especially mono-halogen substituted sulphonamides and sulphonohydrazines bearing a para-chloro or para-bromo phenyl group. The standout molecule was N-(4-chlorophenyl)-N-(trichloromethylthio) thiophene-2-sulphonamide, demonstrating broad spectrum inhibition with MIC_{50} and MIC_{100} values of 86 µmol and 180 µmol, respectively. In contrast, isoxazole analogues showed notably lower fungitoxic activity, and pyrazole and thiazole analogues were largely inactive. An unusual exception was 4-[2′-(3,4-dichlorobenzylidene)hydrazinosulphonyl]thiophene-2-carboxylic acid, which displayed unexpectedly high antifungal activity relative to related structures [120].

Green chemistry-based synthetic methodologies have gained increasing attention in both academic and industrial settings, particularly for developing novel and eco-friendly pesticides. In this context, a series of isoxazolyl-pyrimidine derivatives was rationally designed, synthesized, and structurally confirmed using elemental analysis, ^1H NMR, ^13C NMR, LC-MS, and HPLC. Most of the compounds exhibited high purity (>98% a/a for several molecules). The newly synthesized derivatives were evaluated for antifungal activity against agriculturally important phytopathogens, including Rhizoctonia solani, Sclerotium rolfsii, and Macrophomina phaseolina. Compounds 5d, 5h, and 5l exhibited remarkable inhibitory effects, with inhibition percentages exceeding 70% across all tested fungi. The proposed antifungal mechanism involves inhibition of oxygen activation at the HEME iron center of membrane-bound 14α-demethylase, a key fungal biosynthetic enzyme. The presence of the pyrimidine moiety was identified as a critical structural determinant for activity, further supported by DFT studies, molecular docking, and molecular dynamic simulations [121].

An efficient method was developed for synthesising isoxazoles. A series of novel bis-isoxazole ether compounds VI, VII and VIII were synthesised starting from different substituted aldehydes (I) via a 1,3-dispolar cycloaddition using Zn/Zn2+ as a catalyst; these were characterised by FT-IR, HRMS, 1H NMR and 13C NMR spectroscopy. In addition, the antimicrobial properties of the synthesised products were investigated. The synthesised compounds exhibited significant antifungal activities in comparison with the standard drugs, fluconazole and itraconazole. It was found that Candida albicans was sensitive to 2-substituted phenyl bis-isoxazole ethers bearing pyridyl [122].

4.1.5 Antibacterial Activity:

A facile and highly efficient synthetic approach was developed for preparing a range of pyrazoloisoxazole, isoxazolopyridine, and isoxazolopyrimidine derivatives by reacting an isoxazolone intermediate with various nitrogen nucleophiles. The synthetic transformations were performed under simple grinding conditions, supporting rapid reaction rates, reduced solvent consumption, and improved eco-efficiency. The key intermediate, 4-(4-chlorobenzylidene)-3-phenylisoxazol-5(4H)-one, served as the central scaffold for constructing the new heterocyclic systems. Structural elucidation of the synthesized compounds was achieved through spectral analyses. Nine selected compounds were assessed for antibacterial potential, demonstrating moderate activity against both Gram-positive and Gram-negative strains. These findings indicate that coupling an isoxazolone core with diverse nitrogen nucleophiles provides a promising route for generating new heterocycles with potential biological utility. The simplicity of the methodology and the biological relevance of the products suggest that this strategy can be further expanded for designing and optimizing new pharmacologically active isoxazole-based molecular frameworks [123].

A series of new bioactive cinnoline/ Isoxazole hybrid heterocyclics (7a-p) have been designed and synthesized from cinnoline by applying the regioselective nitrile oxide[1,3]-dipolar cycloadditions. All the synthesised compoundswere screened for their in vitro antibacterial activity. The results of screening revealed that compounds 7f, 7g, 7k, 7l, and 7o are potent antibacterial agents against the Gram- positive bacterial species Bacillus subtilis and Staphylococcus aureus as well as Gram- negative bacterial species Pseudomonas aeruginosa and Escherichia coli. When compared with the standard drug norfloxacin, compound 7k showed more potent antibacterial activity against the all Gram-positive and Gram-negative strains of bacteria. To understand the binding interactions of the most derivatives 7f, 7g, 7k, 7l and 7k molecular docking studies were performed with elastase of Pseudomonas aeruginosa (PDB: 1U4G). These docking results revealed that this class of compounds have potential antibacterial activity [124].

Isoxazole and its derivatives occur only rarely in nature, yet they continue to gain significant attention due to their wide spectrum of biological applications in pharmaceutical science, including antimicrobial, anticancer, antifungal, and antibacterial effects. In a recent investigation, a novel one-pot green synthetic approach was developed to obtain new oxazole derivatives, which were subsequently evaluated for antibacterial and antioxidant potential, supported by DFT analysis. The synthesized compounds were structurally characterized by IR, ^1H NMR, ^13C NMR, CHN analysis, and single-crystal X-ray crystallography. Antibacterial screening was performed against S. aureus and E. coli using Gentamycin as reference, and derivatives 4a, 4c, 4d, 4f, 4j, and 4k showed remarkable activity against S. aureus, whereas 4c and compound 5 were most potent against E. coli. Antioxidant evaluation (ABTS, DPPH, and TAC assays) also revealed strong radical scavenging efficiency for 4a, 4d, 4e, 4k, 4l, 4m, and 5. DFT studies (B3LYP/6-311+G(d,p)) further provided insights into electronic structure, reactivity descriptors, and frontier orbital energy gaps [125].

4.1.6 Antioxidant Activity:

Fluorophenyl–isoxazole–carboxamide derivatives previously reported in literature were re-synthesized to evaluate their free-radical scavenging potential and enzyme inhibitory properties. Biological assays demonstrated that while these compounds exhibited weak inhibition against lipase and α-amylase, they showed remarkable antioxidant potency in the DPPH assay. Among the tested molecules, derivatives 2a and 2c displayed the highest radical scavenging activity with IC_{50} values of 0.45 ± 0.21 μg/mL and 0.47 ± 0.33 μg/mL, respectively, outperforming the standard antioxidant Trolox ($IC_{50} = 3.10 \pm 0.92$ μg/mL). Based on these promising in vitro results, compound 2a was further evaluated in vivo using an intraperitoneal mouse model. The total antioxidant capacity of mice treated with 2a was found to be nearly two-fold higher than that of mice treated with quercetin, indicating strong systemic antioxidant effects. Although additional mechanistic, biological, and preclinical studies remain necessary, these findings highlight the potential of fluorophenyl–isoxazole–carboxamides particularly 2a as promising antioxidant lead candidates [126].

In the present study, we biologically evaluated 30 compounds, including 15 isoxazole ring-containing chalcones (17–31) and 15 dihydropyrazoles (32–46) derived from these chalcones for their antimicrobial, antioxidant, and anticancer activities. Chalcones exhibited superior antibacterial and antioxidant activities compared to dihydropyrazoles. Among the chalcones, compound 28 showed potent antibacterial (MIC = 1 μg/mL) and antioxidant activities (IC50 = 5 ± 1 μg/mL). Dihydropyrazoles, on the contrary, demonstrated remarkable antifungal and anticancer activities. Compound 46 (IC50 = 2 ± 1 μg/mL) showed excellent antifungal activity whereas two other dihydropyrazoles 45 (IC50 = 2 ± 1 μg/mL) and 39 (IC50 = 4 ± 1 μg/mL) exhibited potential anticancer activity. The compounds were also tested for their toxicity on normal human cell lines (LO2) and were found to be nontoxic. The active compounds that have emerged out of this study are potential lead molecules for the development of novel drugs against infectious diseases, oxidative stress, and cancer [127].

5-Lipoxygenase (5-LOX) plays a central role in leukotriene biosynthesis and is strongly implicated in inflammatory disorders such as asthma, making the development of 5-LOX inhibitors an important therapeutic strategy. In a recent study, previously synthesized isoxazole derivatives were evaluated for both in vitro 5-LOX inhibition and antioxidant potential. Compound C3 demonstrated the highest antioxidant effect with an IC_{50} of 10.96 µM, whereas C6 emerged as the most potent 5-LOX inhibitor overall, showing strong concentration-dependent activity comparable to the reference standard. Compound C5 also showed notable dual activity, with IC_{50} values of 10.48 µM for 5-LOX inhibition and 13.12 µM for radical scavenging. Additionally, C6 exhibited high percentage inhibition across a wide concentration range (1000–62.5 µg/mL). In silico docking studies supported the experimental findings, indicating strong binding of the most active compounds within the enzyme active site. Overall, C3, C5, and particularly C6 demonstrated promising dual anti-inflammatory and antioxidant activity profiles [128].

4.2 Mechanism of Action:

Isoxazole derivatives exert their biological activities through multiple mechanisms, primarily involving enzyme inhibition, receptor modulation, and disruption of vital cellular pathways. The five-membered heterocyclic ring, composed of oxygen and nitrogen atoms, allows these compounds to form strong hydrogen bonds and coordinate interactions with target biomolecules. These interactions lead to the inhibition of key enzymes such as cyclooxygenases, DNA gyrases, and sterol demethylases, depending on the therapeutic target. Their chemical versatility and electronic properties make isoxazoles valuable pharmacophores capable of influencing enzyme catalysis, signal transduction, and nucleic acid synthesis in microbial, viral, and mammalian systems [129].

4.2.1 Enzymatic Inhibition and Binding Targets:

Isoxazole derivatives demonstrate a diverse range of enzyme inhibitory mechanisms, contributing to their antimicrobial, anti-inflammatory, antiviral, and anticancer activities. The planar isoxazole ring enables π–π stacking, hydrogen bonding, and dipole interactions within enzyme active sites. For instance, antibacterial isoxazoles inhibit DNA gyrase and topoisomerase IV, preventing bacterial DNA replication. Antifungal derivatives target lanosterol 14α-demethylase (CYP51) and squalene epoxidase, interrupting ergosterol biosynthesis. In anti-inflammatory action, isoxazole scaffolds selectively bind to COX-2 and 5-LOX, reducing prostaglandin and leukotriene formation. Similarly, antiviral isoxazoles interact with viral polymerases, proteases, and kinases, blocking replication. The presence of substituents such as halogens or methoxy groups enhances enzyme binding through hydrophobic and electron-withdrawing effects. Thus, enzyme inhibition remains a central mechanism underlying the pharmacological potential of isoxazole-based compounds [130, 131].

4.2.2 Role of Heteroatoms in Biological Activity:

The heteroatoms (oxygen and nitrogen) within the isoxazole ring play a critical role in modulating biological activity and target affinity. These atoms contribute to electronic delocalization, enhancing molecular stability and enabling hydrogen bond formation with active-site residues of enzymes and receptors. The nitrogen atom often acts as a hydrogen bond acceptor, improving interactions with nucleophilic centers such as amino acid side chains or nucleic acid bases. Meanwhile, the oxygen atom influences polarity and lipophilicity, facilitating passive diffusion across biological membranes. This dual heteroatom configuration also promotes selective binding to metal cofactors and catalytic residues, stabilizing enzyme–inhibitor complexes. In certain hybrids, these atoms contribute to electron withdrawal or donation, fine-tuning reactivity and metabolic stability. Collectively, the heteroatomic nature of isoxazole imparts exceptional flexibility, allowing it to interact with a wide spectrum of biological targets while maintaining pharmacokinetic balance and therapeutic potency [132, 133].

4.3 Comparative Pharmacological Potency:

Both isoxazole and benzimidazole derivatives are renowned heterocyclic scaffolds with broad-spectrum pharmacological activities, including antimicrobial, anti-inflammatory, antiviral, and anticancer effects. Despite structural differences, both share similar physicochemical traits planarity, aromaticity, and heteroatom-based hydrogen bonding that enable strong interactions with biological macromolecules. However, variations in their electronic distribution and substituent flexibility influence target specificity and potency. Comparative analyses reveal that while benzimidazoles often excel in enzyme inhibition and DNA binding, isoxazoles demonstrate superior selectivity, metabolic stability, and multi-target potential, making them valuable frameworks in modern drug discovery and hybrid pharmacophore design.

4.3.1 Comparative Efficacy of Isoxazole with Benzimidazole Derivatives:

The comparative efficacy of isoxazole and benzimidazole derivatives depends on the biological target and substituent modifications. Benzimidazole derivatives are highly effective in enzyme inhibition and DNA intercalation, displaying potent anticancer and antiparasitic activity due to their bicyclic nitrogen framework and π–π stacking potential. They exhibit strong affinity toward tubulin, topoisomerase II, and DNA polymerases, making them excellent cytotoxic and antimicrobial agents. Conversely, isoxazole derivatives, with their oxygen–nitrogen heterocycle, show enhanced metabolic stability, membrane permeability, and COX-2 selectivity, favoring anti-inflammatory and antiviral applications. Isoxazoles often display higher target specificity and reduced off-target toxicity owing to their balanced lipophilicity and electronic properties. Comparative SAR studies have demonstrated that hybridization of isoxazole with other heterocycles yields compounds with broader efficacy than benzimidazoles alone, particularly in inflammation, infection, and cancer models. Thus, both scaffolds complement each other through distinct mechanistic strengths [134, 135].

4.3.2 Combination Potential in Multi-Target Drug Design:

The combination of isoxazole and benzimidazole pharmacophores offers a promising strategy in multi-target drug design, addressing the complexity of diseases involving multiple biochemical pathways. Isoxazole derivatives contribute COX inhibition, kinase modulation, and antioxidant properties, while benzimidazole derivatives offer DNA interaction and enzyme inhibition capabilities. Their hybridization can yield compounds capable of dual or triple mechanistic action, beneficial in conditions such as cancer, inflammation, and microbial resistance. Recent hybrid molecules, such as benzimidazole–isoxazole conjugates, have exhibited synergistic potency, with improved binding to both protein kinases and DNA gyrase, alongside favorable ADMET properties. The complementary features isozaxole's selectivity and benzimidazole's binding strength enhance bioefficacy while reducing toxicity and resistance. Hence, rationally designed hybrid scaffolds incorporating both heterocycles represent a forward-looking approach in polypharmacology and precision medicine [136, 137].

5. Challenges and Future Directions:

Despite significant pharmacological advancements, several challenges persist in the development of benzimidazole and isoxazole derivatives. The foremost limitations lies in the complexity and inefficiency of current synthesis strategies, which often require harsh reaction conditions, toxic reagents, and multistep processes that lower yield and reproducibility. These issues hinder large-scale production and industrial translation. Hence, there is an urgent need to adopt sustainable and green chemistry approaches, including solvent-free, microwave-assisted, and biocatalytic methods that minimize environmental impact while improving reaction efficiency and selectivity [138].

The incorporation of computational prediction and AI-assisted molecular design has emerged as a transformative tool for drug discovery. Machine learning algorithms, molecular docking, and quantitative structure–activity relationship (QSAR) models can predict binding affinities, optimize pharmacokinetic properties, and reduce experimental costs. Such in silico strategies allow researchers to rapidly identify potent lead molecules and streamline the design–synthesis–testing cycle [139].

In the therapeutic domain, emerging targets such as multidrug-resistant infections, cancer signaling pathways, and viral proteases offer vast potential for benzimidazole and isoxazole-based agents. However, translating laboratory findings into clinical candidates demands better pharmacodynamic profiling, toxicity evaluation, and formulation stability. Patent and industrial trends indicate growing interest in heterocyclic hybrids and nanocarrier-based formulations incorporating benzimidazole and isoxazole scaffolds. The future lies in integrating synthetic innovation, green chemistry, and computational intelligence to develop next-generation multifunctional drugs with enhanced efficacy, safety, and sustainability bridging the gap between academic discovery and pharmaceutical application [140-141].

6. CONCLUSION:

The exploration of benzimidazole and isoxazole derivatives underscores their enduring importance as privileged scaffolds in medicinal chemistry. Their structural diversity, pharmacophoric flexibility, and ability to engage in multifaceted interactions with biological targets make them invaluable frameworks for drug discovery. Through strategic substitution, hybridization, and green synthesis, researchers have developed derivatives exhibiting potent antimicrobial, antiviral, anticancer, anti-inflammatory, antioxidant, and antifungal activities. Comparative analyses reveal that while benzimidazoles excel in enzyme inhibition, DNA binding, and receptor modulation, isoxazoles offer superior selectivity, metabolic stability, and anti-inflammatory potential. Advancements in synthetic methodologies from microwave-assisted and nanocatalytic reactions to solvent-free and bio-catalyzed processes have revolutionized the efficiency and sustainability of heterocycle synthesis. Furthermore, computational approaches, including molecular docking, QSAR, and AI-assisted predictive modeling, have accelerated the identification and optimization of potent analogs with desirable pharmacokinetic profiles. Despite significant progress, challenges remain, particularly in overcoming resistance, enhancing bioavailability, and minimizing toxicity. Future research should focus on integrating green chemistry principles, data-driven molecular design, and nanotechnology to create multifunctional hybrids capable of addressing complex diseases through multi-target mechanisms. The combined study of benzimidazole and isoxazole frameworks exemplifies the synergy between classical medicinal chemistry and modern computational innovation. Their continued evolution will play a pivotal role in the development of next-generation therapeutics, contributing to safer, more effective, and sustainable healthcare solutions.

7. AUTHORS CONTRIBUTION

It is hereby acknowledged that all authors have accepted responsibility for the manuscript's content and consented to its submission. They have meticulously reviewed all results and unanimously approved the final version of the manuscript.

8. CONSENT FOR PUBLICATION

Not applicable.

9. FUNDING

None.

10. CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose.

11. ACKNOWLEDGMENT

Declared none.

12. REFERENCES

1. Ebenezer O, Jordaan MA, Carena G, Bono T, Shapi M, Tuszynski JA. An overview of the biological evaluation of selected nitrogen-containing heterocycle medicinal chemistry compounds. International Journal of Molecular Sciences. 2022 Jul 23;23(15):8117.
2. Kumar N, Goel N. Heterocyclic compounds: importance in anticancer drug discovery. Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents). 2022 Nov 1;22(19):3196-207.
3. Baranwal J, Kushwaha S, Singh S, Jyoti A. A review on the synthesis and pharmacological activity of heterocyclic compounds. Current Physical Chemistry. 2023 Mar 1;13(1):2-19.
4. Sarvaiya BH, Vaja PI, Paghdar NA, Ghelani SM. Medicinal perspective of a promising scaffold–dihydropyrimidinones: A review. Journal of Heterocyclic Chemistry. 2024 Aug;61(8):1325-48.
5. Baranwal J, Kushwaha S, Singh S, Jyoti A. A review on the synthesis and pharmacological activity of heterocyclic compounds. Current Physical Chemistry. 2023 Mar 1;13(1):2-19.
6. Amin A, Qadir T, Sharma PK, Jeelani I, Abe H. A review on the medicinal and industrial applications of N-containing heterocycles. The Open Medicinal Chemistry Journal. 2022 Nov 16;16(1).
7. Rusu A, Moga IM, Uncu L, Hancu G. The role of five-membered heterocycles in the molecular structure of antibacterial drugs used in therapy. Pharmaceutics. 2023 Oct 29;15(11):2554.
8. Martis GJ, Gaonkar SL. Advances in isoxazole chemistry and their role in drug discovery. RSC advances. 2025;15(11):8213-43.
9. Prajapati RN, Bhushan B, Singh K, Chopra H, Kumar S, Agrawal M, Pathak D, Chanchal DK, Laxmikant. Recent advances in pharmaceutical design: unleashing the potential of novel therapeutics. Current Pharmaceutical Biotechnology. 2024 Dec 1;25(16):2060-77.
10. Singh H, Kumar R, Tiwari P, Singh A. Recent advances in synthetic strategies of benzimidazole and its analogs: A review. Current Organic Chemistry. 2022 Oct 1;26(19):1767-78.
11. Grazia Martina M, Giannessi L, Radi M. Multicomponent synthesis of purines and pyrimidines: From the origin of life to new sustainable approaches for drug-discovery applications. European Journal of Organic Chemistry. 2023 Jan 10;26(2):e202201288.
12. Chai JY, Jung BK, Hong SJ. Albendazole and mebendazole as anti-parasitic and anti-cancer agents: an update. The Korean journal of parasitology. 2021 Jun 30;59(3):189.
13. Alam W, Khan H, Saeed Jan M, Rashid U, Abusharha A, Daglia M. Synthesis, in-vitro inhibition of cyclooxygenases and in silico studies of new isoxazole derivatives. Frontiers in chemistry. 2023 Sep 6;11:1222047.
14. Hawash M, Jaradat N, Abualhasan M, Qneibi M, Rifai H, Saqfelhait T, Shqirat Y, Nazal A, Omarya S, Ibrahim T, Sobuh S. Evaluation of cytotoxic, COX inhibitory, and antimicrobial activities of novel isoxazole-carboxamide derivatives. Letters in Drug Design & Discovery. 2023 Dec 1;20(12):1994-2002.
15. Shinde Y, Khairnar B, Bangale S. Exploring the diverse biological frontiers of isoxazole: a comprehensive review of its pharmacological significance. ChemistrySelect. 2024 Aug 27;9(32):e202401423.
16. Ebenezer O, Jordaan MA, Carena G, Bono T, Shapi M, Tuszynski JA. An overview of the biological evaluation of selected nitrogen-containing heterocycle medicinal chemistry compounds. International Journal of Molecular Sciences. 2022 Jul 23;23(15):8117.
17. Elango H, Das RN, Saha A. Benzimidazole-based small molecules as anticancer agents targeting telomeric G-quadruplex and inhibiting telomerase enzyme. Future Medicinal Chemistry. 2024 Oct 1;16(19):2043-67.
18. Li SR, Tan YM, Zhang L, Zhou CH. Comprehensive insights into medicinal research on imidazole-based supramolecular complexes. Pharmaceutics. 2023 Apr 27;15(5):1348.
19. Iorkula TH, Osayawe OJ, Odogwu DA, Ganiyu LO, Faderin E, Awoyemi RF, Akodu BO, Ifijen IH, Aworinde OR, Agyemang P, Onyinyechi OL. Advances in pyrazolo [1, 5-a] pyrimidines: synthesis and their role as protein kinase inhibitors in cancer treatment. RSC advances. 2025;15(5):3756-828.
20. Pandhurnekar CP, Pandhurnekar HC, Mungole AJ, Butoliya SS, Yadao BG. A review of recent synthetic strategies and biological activities of isoxazole. Journal of Heterocyclic Chemistry. 2023 Apr;60(4):537-65.
21. Sivaraj N, Sakthivel K, Kikushima K, Kostić MD, Dohi T, Singh FV. Recent advances in non-conventional synthesis of N-heterocyclic compounds: emerging strategies and biological perspectives. RSC advances. 2025;15(42):35509-31.
22. Natarajan R, Kumar P, Subramani A, Siraperuman A, Angamuthu P, Bhandare RR, Shaik AB. A critical review on therapeutic potential of benzimidazole derivatives: a privileged scaffold. Medicinal Chemistry. 2024 Mar 1;20(3):311-51.
23. Guan Q, Xing S, Wang L, Zhu J, Guo C, Xu C, Zhao Q, Wu Y, Chen Y, Sun H. Triazoles in medicinal chemistry: physicochemical properties, bioisosterism, and application. Journal of Medicinal Chemistry. 2024 May 3;67(10):7788-824.
24. Sharma P, LaRosa C, Antwi J, Govindarajan R, Werbovetz

KA. Imidazoles as potential anticancer agents: An update on recent studies. Molecules. 2021 Jul 11;26(14):4213.

25. Ziaie ZM, Mokhtary M. A Theoretical Investigation of Heterocycles with N–O Bonds Understanding the Biological Effects and Theoretical Studies: From Theory to Applicatio. J. Chem. Rev. 2025;7(2):166-90.
26. Madhavan S, Keshri SK, Kapur M. Transition Metal-Mediated Functionalization of Isoxazoles: A Review. Asian Journal of Organic Chemistry. 2021 Dec;10(12):3127-65.
27. Bansal Y, Minhas R, Singhal A, Arora RK, Bansal G. Benzimidazole: A multifacted nucelus for anticancer agents. Current Organic Chemistry. 2021 Mar 1;25(6):669-94.
28. Satija G, Sharma B, Madan A, Iqubal A, Shaquiquzzaman M, Akhter M, Parvez S, Khan MA, Alam MM. Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets. Journal of Heterocyclic Chemistry. 2022 Jan;59(1):22-66.
29. Borah B, Veeranagaiah NS, Sharma S, Patat M, Prasad MS, Pallepogu R, Chowhan LR. Stereoselective synthesis of CF 3-containing spirocyclic-oxindoles using N-2, 2, 2-trifluoroethylisatin ketimines: an update. RSC advances. 2023;13(11):7063-75.
30. Kant K, Patel CK, Banerjee S, Naik P, Atta AK, Kabi AK, Malakar CC. Recent advancements in strategies for the synthesis of imidazoles, thiazoles, oxazoles, and benzimidazoles. ChemistrySelect. 2023 Dec 18;8(47):e202303988.
31. Kunjumol VS, Jeyavijayan S, Karthik N, Sumathi S. Spectroscopic, computational, docking, and cytotoxicity investigations of 5-chloro-2-mercaptobenzimidazole as an anti-breast cancer medication. Spectroscopy Letters. 2025 Jan 2;58(1):13-35.
32. Bugden FE, Westwood JL, Stone H, Xu Y, Greenhalgh M. Synthesis and applications of fluorinated, polyfluoroalkyl- and polyfluoroaryl-substituted 1, 2, 3-triazoles. Organic Chemistry Frontiers. 2024;11(20):5938-84.
33. Ahmad S, Jaiswal R, Yadav R, Verma S. Recent advances in green chemistry approaches for pharmaceutical synthesis. Sustainable Chemistry One World. 2024 Dec 1;4:100029.
34. Mamedov VA, Zhukova NA. Recent developments towards synthesis of (Het) arylbenzimidazoles. Synthesis. 2021 Jun;53(11):1849-78.
35. Jaiswal S. Aqua Mediated Multicomponent Synthesis of N, O-Heterocycles and Biological Activity of Fused Isoxazole Derivatives. InFive Membered Bioactive N and O-Heterocycles: Models and Medical Applications 2025 (pp. 495-536). IGI Global Scientific Publishing.
36. Nardi M, Cano NC, Simeonov S, Bence R, Kurutos A, Scarpelli R, Wunderlin D, Procopio A. A review on the green synthesis of benzimidazole derivatives and their pharmacological activities. Catalysts. 2023 Feb 11;13(2):392.
37. Teli S, Teli P, Soni S, Sahiba N, Agarwal S. Synthetic aspects of 1, 4-and 1, 5-benzodiazepines using o-phenylenediamine: A study of past quinquennial. RSC advances. 2023;13(6):3694-714.
38. Basavanna V, Doddamani S, Chandramouli M, Bhadraiah UK, Ningaiah S. Green approaches for the synthesis of pharmacologically enviable isoxazole analogues: a comprehensive review. Journal of the Iranian Chemical Society. 2022 Aug;19(8):3249-83.
39. Sharma J, Soni PK, Bansal R, Halve AK. Synthetic approaches towards benzimidazoles by the reaction of o-phenylenediamine with aldehydes using a variety of catalysts: a review. Current Organic Chemistry. 2018 Oct 1;22(23):2280-99.
40. Algethami FK, Cherif M, Jlizi S, Ben Hamadi N, Romdhane A, Elamin MR, Alghamdi MA, Ben Jannet H. Design, microwave-assisted synthesis and in silico prediction study of novel isoxazole linked pyranopyrimidinone conjugates as new targets for searching potential Anti-SARS-CoV-2 agents. Molecules. 2021 Oct 10;26(20):6103.
41. Singhal S, Khanna P, Panda SS, Khanna L. Recent trends in the synthesis of benzimidazoles from o-phenylenediamine via nanoparticles and green strategies using transition metal catalysts. Journal of Heterocyclic Chemistry. 2019 Oct;56(10):2702-29.
42. Damian CS, Devarajan Y, T R. Nanocatalysts in Biodiesel Production: Advancements, Challenges, and Sustainable Solutions. ChemBioEng Reviews. 2025 Apr;12(2):e202400055.
43. Agrwal A, Rai P, Kumar V. Recent Developments in Heterogeneous Nano Catalyst for Green Synthesis: A Review. Topics in Catalysis. 2025 Jun 2:1-9.
44. Keri RS, Adimule V, Kendrekar P, Sasidhar BS. The nano-based catalyst for the synthesis of benzimidazoles. Topics in Catalysis. 2025 Jul;68(13):1449-69.
45. Kornet MM, Müller TJ. Recent Advances in Sequentially Pd-Catalyzed One-Pot Syntheses of Heterocycles. Molecules. 2024 Nov 7;29(22):5265.
46. Sharma RK, Bandichhor R, Mishra V, Sharma S, Yadav S, Mehta S, Arora B, Rana P, Dutta S, Solanki K. Advanced metal oxide-based nanocatalysts for the oxidative synthesis of fine chemicals. Materials Advances. 2023;4(8):1795-830.
47. Ponce S, Murillo HA, Alexis F, Alvarez-Barreto J, Mora JR. Green synthesis of nanoparticles mediated by deep eutectic solvents and their applications in water treatment. Sustainability. 2023 Jun 17;15(12):9703.
48. Lasso JD, Castillo-Pazos DJ, Li CJ. Green chemistry meets medicinal chemistry: a perspective on modern metal-free late-stage functionalization reactions. Chemical Society Reviews. 2021;50(19):10955-82.
49. Chen MT, Li YR, Wang ZQ, Jiang S, Jia ZH, Zhang DW. The Green and Effective Synthesis of Isoxazole-Based Molecules Under Ultrasonic Irradiation Approaches. Pharmaceuticals. 2025 Aug 10;18(8):1179.
50. Panda SS, Hansen DW. Microwave-assisted synthesis of five-membered azaheterocyclic systems using nanocatalysts. InNanoparticles in Green Organic Synthesis 2023 Jan 1 (pp. 255-278). Elsevier.
51. Veerasamy R, Roy A, Karunakaran R, Rajak H. Structure–activity relationship analysis of benzimidazoles as emerging anti-inflammatory agents: An overview. Pharmaceuticals. 2021 Jul 11;14(7):663.
52. Poyraz S, Yıldırım M, Ersatir M. Recent pharmacological insights about imidazole hybrids: a comprehensive review. Medicinal Chemistry Research. 2024 Jun;33(6):839-68.
53. Rahaman TA, Chaudhary S. Targeting cancer using scaffold-hopping approaches: illuminating SAR to improve drug design. Drug discovery today. 2024 Sep 1;29(9):104115.
54. Bakheit AH, Wani TA, Al-Majed AA, Alkahtani HM, Alanazi MM, Alqahtani FR, Zargar S. Theoretical study of the antioxidant mechanism and structure-activity relationships of 1, 3, 4-oxadiazol-2-ylthieno [2, 3-d] pyrimidin-4-amine derivatives: a computational approach. Frontiers in Chemistry. 2024 Jul 30;12:1443718.
55. Farag B, Zaki ME, Elsayed DA, Gomha SM. Benzimidazole chemistry in oncology: recent developments in synthesis, activity, and SAR analysis. RSC advances. 2025;15(23):18593-647.
56. Qneibi M. Isoxazole-Carboxamide Modulators of GluA2-Containing α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic Acid Receptors in Parkinson's Disease. Chemistry & Biodiversity. 2025 Mar 29:e202500392.
57. Agrawal N. A Comprehensive Review on the Advancements of Dual COX-2/5-LOX Inhibitors as Anti-Inflammatory Drugs. Chemical Biology & Drug Design. 2025 May;105(5):e70114.
58. Mondal P, Manna S, Ganguly P, Irfan Z, Mondal S. Design, Synthesis, and Pharmacological Evaluation of Novel Isatin Scaffolds as Potent Anti-Inflammatory and Antibacterial Agents. ChemistrySelect. 2025 Jun;10(22):e00992.

59. Gujjarappa R, Sravani S, Kabi AK, Garg A, Vodnala N, Tyagi U, Kaldhi D, Singh V, Gupta S, Malakar CC. An overview on biological activities of oxazole, isoxazoles and 1, 2, 4-oxadiazoles derivatives. Nanostructured biomaterials: basic structures and applications. 2022 Mar 8:379-400.
60. Sahoo BM, Kumar BV, Panda KC, Banik BK, Tiwari A, Tiwari V, Singh S, Kumar M. Isoxazole Derivatives as Potential Pharmacophore for New Drug Development. InFrontiers in Medicinal Chemistry: Volume 10 2023 Oct 26 (pp. 1-49). Bentham Science Publishers.
61. Brishty SR, Hossain MJ, Khandaker MU, Faruque MR, Osman H, Rahman SA. A comprehensive account on recent progress in pharmacological activities of benzimidazole derivatives. Frontiers in pharmacology. 2021 Nov 3;12:762807.
62. Khatun S, Singh A, Bader GN, Sofi FA. Imidazopyridine, a promising scaffold with potential medicinal applications and structural activity relationship (SAR): recent advances. Journal of Biomolecular Structure and Dynamics. 2022 Dec 26;40(24):14279-302.
63. Knipe AC. Reactions of Aldehydes and Ketones and their Derivatives. Organic Reaction Mechanisms• 2012: An annual survey covering the literature dated January to December 2012. 2015 Jun 2:1-50.
64. Rezaeifard A, Doraghi F, Akbari F, Bari B, Kianmehr E, Ramazani A, Khoobi M, Foroumadi A. Organic Peroxides in Transition-Metal-Free Cyclization and Coupling Reactions (C–C) via Oxidative Transformation. ACS omega. 2025 Apr 14;10(16):15852-907.
65. Sarkar A, Santra S, Kundu SK, Hajra A, Zyryanov GV, Chupakhin ON, Charushin VN, Majee A. A decade update on solvent and catalyst-free neat organic reactions: a step forward towards sustainability. Green Chemistry. 2016;18(16):4475-525.
66. Majhi S, Manickam S, Cravotto G. Solvent-free and aqueous organic synthesis using ultrasound toward sustainable society. InSonochemistry 2024 Aug 30 (pp. 91-112). CRC Press.
67. Avarsaji M, Hossaini Z, Varasteh Moradi A, Jalilian HR, Zafar Mehrabian R. Synthesis and biological activity investigation of new oxazolopyrimidoazepine derivatives: Application of Ag/Fe3O4/TiO2/CuO@ MWCNTs MNCs in the reduction of organic pollutants. Polycyclic Aromatic Compounds. 2023 Aug 9;43(7):5996-6017.
68. Tiglani D, Salahuddin, Mazumder A, Yar MS, Kumar R, Ahsan MJ. Benzimidazole-quinoline hybrid scaffold as promising pharmacological agents: a review. Polycyclic Aromatic Compounds. 2022 Sep 14;42(8):5044-66.
69. Naqvi AA, Mohammad T, Hasan GM, Hassan MI. Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships. Current topics in medicinal chemistry. 2018 Aug 1;18(20):1755-68.
70. Evren AE, Kaya AZ, Karakaya A, Tutuş B, Güngör EM, Nuha D, Osmaniye D, Kaya B, Çevik UA, Yurttaş L, Kaplancikli ZA. Latest developments in small molecule analgesics: heterocyclic scaffolds I. Future Medicinal Chemistry. 2025 Aug 3;17(15):1899-918.
71. Staszak M, Staszak K, Wieszczycka K, Bajek A, Roszkowski K, Tylkowski B. Machine learning in drug design: Use of artificial intelligence to explore the chemical structure–biological activity relationship. Wiley Interdisciplinary Reviews: Computational Molecular Science. 2022 Mar;12(2):e1568.
72. Walker AS, Clardy J. A machine learning bioinformatics method to predict biological activity from biosynthetic gene clusters. Journal of Chemical Information and Modeling. 2021 May 27;61(6):2560-71.
73. Harika G, Kamala GR, Syamala B. The Evolving Role of Artificial Intelligence and Machine Learning in Drug Discovery and Development. Journal of Pharma Insights and Research. 2025 Oct 5;3(5):276-85.
74. Chen J, Xu L, Wang B, Zhang D, Zhao L, Bei Z, Song Y. Design, synthesis, and biological evaluation of Benzimidazole derivatives as potential Lassa virus inhibitors. Molecules. 2023 Feb 7;28(4):1579.
75. Obaid RJ. New benzimidazole derivatives: Design, synthesis, docking, and biological evaluation. Arabian Journal of Chemistry. 2023 Feb 1;16(2):104505.
76. Yadav G, Ganguly S, Murugesan S, Dev A. Synthesis, anti-HIV, antimicrobial evaluation and structure activity relationship studies of some novel benzimidazole derivatives. Anti-infective agents. 2015 Apr 1;13(1):65-77.
77. Morcoss MM, El Shimaa MN, Ibrahem RA, Abdel-Rahman HM, Abdel-Aziz M, Abou El-Ella DA. Design, synthesis, mechanistic studies and in silico ADME predictions of benzimidazole derivatives as novel antifungal agents. Bioorganic chemistry. 2020 Aug 1;101:103956.
78. Yang L. Design, Synthesis, and antifungal activity of novel benzimidazole derivatives bearing thioether and carbamate moieties. Journal of Chemistry. 2022;2022(1):8646557.
79. Khabnadideh S, Rezaei Z, Khalafi-Nezhad A, Pakshir K, Roosta A, Baratzadeh Z. Design and Synthesis of imidazole and benzimidazole derivatives as antifungal agents. Anti-Infective Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Infective Agents). 2008 Jul 1;7(3):215-8.
80. Mavrova AT, Yancheva D, Anastassova N, Anichina K, Zvezdanovic J, Djordjevic A, Markovic D, Smelcerovic A. Synthesis, electronic properties, antioxidant and antibacterial activity of some new benzimidazoles. Bioorganic & medicinal chemistry. 2015 Oct 1;23(19):6317-26.
81. Negi DS, Kumar G, Singh M, Singh N. Antibacterial activity of benzimidazole derivatives: A mini review. Research & Reviews: Journal of Chemistry. 2017;6:18-28.
82. Bektaş H, Sökmen BB, Aydın S, Menteşe E, Bektaş A, Dilekçi G. Design, synthesis, and characterization of some new benzimidazole derivatives and biological evaluation. Journal of Heterocyclic Chemistry. 2020 May;57(5):2234-42.
83. Moharana AK, Dash RN, Mahanandia NC, Subudhi BB. Synthesis and anti-inflammatory activity evaluation of some benzimidazole derivatives. Pharmaceutical Chemistry Journal. 2022 Nov;56(8):1070-4.
84. Veerasamy R, Roy A, Karunakaran R, Rajak H. Structure–activity relationship analysis of benzimidazoles as emerging anti-inflammatory agents: An overview. Pharmaceuticals. 2021 Jul 11;14(7):663.
85. Bano S, Nadeem H, Zulfiqar I, Shahzadi T, Anwar T, Bukhari A, Masaud SM. Synthesis and anti-inflammatory activity of benzimidazole derivatives; an in vitro, in vivo and in silico approach. Heliyon. 2024 May 15;10(9).
86. Zhang H, Lin J, Rasheed S, Zhou C. Design, synthesis, and biological evaluation of novel benzimidazole derivatives and their interaction with calf thymus DNA and synergistic effects with clinical drugs. Science China Chemistry. 2014 Jun;57(6):807-22.
87. Srivastava R, Gupta SK, Naaz F, Singh A, Singh VK, Verma R, Singh N, Singh RK. Synthesis, antibacterial activity, synergistic effect, cytotoxicity, docking and molecular dynamics of benzimidazole analogues. Computational biology and chemistry. 2018 Oct 1;76:1-6.
88. Kus C, Ayhan-Kilcgil G, Tuncbilek M, Altanlar N, Coban T, Can-Eke B, Iscan M. Synthesis, antimicrobial and antioxidant activities of some benzimidazole derivatives. Letters in Drug Design & Discovery. 2009 Jul 1;6(5):374-9.
89. Bhandari SV, Nagras OG, Kuthe PV, Sarkate AP, Waghamare KS, Pansare DN, Chaudhari SY, Mawale SN, Belwate MC. Design, synthesis, molecular docking and antioxidant evaluation of benzimidazole-1, 3, 4 oxadiazole derivatives. Journal of Molecular Structure. 2023 Mar 15;1276:134747.
90. Kashid BB, Ghanwat AA, Khedkar VM, Dongare BB, Shaikh MH, Deshpande PP, Wakchaure YB. Design,

synthesis, in vitro antimicrobial, antioxidant evaluation, and molecular docking study of novel benzimidazole and benzoxazole derivatives. Journal of Heterocyclic Chemistry. 2019 Mar;56(3):895-908.

91. Abd El-All AS, Ragab FA, Magd El-Din AA, Abdalla MM, El-Hefnawi MM, El-Rashedy AA. Design, synthesis and anticancer evaluation of some selected Schiff bases derived from benzimidazole derivative. Global J Pharmacology. 2013;7:143-52.
92. Satija G, Sharma B, Madan A, Iqubal A, Shaquiquzzaman M, Akhter M, Parvez S, Khan MA, Alam MM. Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets. Journal of Heterocyclic Chemistry. 2022 Jan;59(1):22-66.
93. Çevik UA, Osmaniye D, Çavuşoğlu BK, Sağlik BN, Levent S, Ilgin S, Can NÖ, Özkay Y, Kaplancikli ZA. Synthesis of novel benzimidazole–oxadiazole derivatives as potent anticancer activity. Medicinal Chemistry Research. 2019 Dec;28(12):2252-61.
94. Sharma NK, Bahot A, Sekar G, Bansode M, Khunteta K, Sonar PV, Hebale A, Salokhe V, Sinha BK. Understanding cancer's defense against topoisomerase-active drugs: A comprehensive review. Cancers. 2024 Feb 6;16(4):680.
95. Aliabadi A, Moradi SZ, Abdian S, Fakhri S, Echeverría J. Critical dysregulated signaling pathways in drug resistance: highlighting the repositioning of mebendazole for cancer therapy. Frontiers in Pharmacology. 2025 Jul 25;16:1631419.
96. Gniazdowski M, Denny WA, Nelson SM, Czyz M. Effects of anticancer drugs on transcription factor–DNA interactions. Expert opinion on therapeutic targets. 2005 Jun 1;9(3):471-89.
97. Hussain A, AlAjmi MF, Rehman MT, Khan AA, Shaikh PA, Khan RA. Evaluation of transition metal complexes of benzimidazole-derived scaffold as promising anticancer chemotherapeutics. Molecules. 2018 May 21;23(5):1232.
98. Tahlan S, Singh S, Kaira M, Dey H, Pandey KC. Benzimidazole-Based Anthelmintic Drugs: Synthetic Strategy, Pharmacological Insights, and SAR Analysis. ChemistrySelect. 2025 Mar;10(10):e202405873.
99. Ceballos L, Nieves E, Juárez M, Aveldaño R, Travacio M, Martos J, Cimino R, Walson JL, Krolewiecki A, Lanusse C, Alvarez L. Assessment of diet-related changes on albendazole absorption, systemic exposure, and pattern of urinary excretion in treated human volunteers. Antimicrobial agents and chemotherapy. 2021 Aug 17;65(9):10-128.
100. Rashid MR. Benzimidazole molecule as new anticancer agent; Design, synthesis and ADMET prediction. Journal of the Chilean Chemical Society. 2021 Jun 13;66(2):5164-82.
101. Ersan RH, Kuzu B, Yetkin D, Alagoz MA, Dogen A, Burmaoglu S, Algul O. 2-Phenyl substituted Benzimidazole derivatives: Design, synthesis, and evaluation of their antiproliferative and antimicrobial activities. Medicinal Chemistry Research. 2022 Jul;31(7):1192-208.
102. Özdemir A, Sever B, Altıntop MD. New benzodioxole-based pyrazoline derivatives: Synthesis and anticandidal, in silico ADME, molecular docking studies. Letters in Drug Design & Discovery. 2019 Jan 1;16(1):82-92.
103. Desenko SM, Gorobets MY, Lipson VV, Sakhno YI, Chebanov VA. Dihydroazolopyrimidines: Past, present and perspectives in synthesis, green chemistry and drug discovery. The Chemical Record. 2024 Feb;24(2):e202300244.
104. Maghraby MT, Abou-Ghadir OM, Abdel-Moty SG, Ali AY, Salem OI. Novel class of benzimidazole-thiazole hybrids: The privileged scaffolds of potent anti-inflammatory activity with dual inhibition of cyclooxygenase and 15-lipoxygenase enzymes. Bioorganic & medicinal chemistry. 2020 Apr 1;28(7):115403.
105. Mittal A, Vashistha VK, Das DK. Recent advances in the antioxidant activity and mechanisms of chalcone derivatives: a computational review. Free Radical Research. 2022 Jun 3;56(5-6):378-97.
106. Sidat PS, Jaber TM, Vekariya SR, Mogal AM, Patel AM, Noolvi M. Anticancer biological profile of some heterocylic moieties-thiadiazole, benzimidazole, quinazoline, and pyrimidine. Pharmacophore. 2022;13(4-2022):59-71.
107. Zhang F, Graham J, Zhai T, Liu Y, Huang Z. Discovery of MurA Inhibitors as Novel Antimicrobials through an Integrated Computational and Experimental Approach. Antibiotics 2022, 11, 528 [Internet]. 2022
108. Fonkui TY, Ikhile MI, Njobeh PB, Ndinteh DT. Benzimidazole Schiff base derivatives: synthesis, characterization and antimicrobial activity. BMC chemistry. 2019 Nov 9;13(1):127.
109. Wang X, Ling N, Che QT, Zhang YW, Yang HX, Ruan Y, Zhao TT. Synthesis, structure and biological properties of benzimidazole-based Cu (II)/Zn (II) complexes. Inorganic Chemistry Communications. 2019 Jul 1;105:97-101.
110. Liu B, Jiang D, Hu G. The antibacterial activity of isatin hybrids. Current Topics in Medicinal Chemistry. 2022 Jan 1;22(1):25-40.
111. Yang Z, Li P, Gan X. Novel pyrazole-hydrazone derivatives containing an isoxazole moiety: Design, synthesis, and antiviral activity. Molecules. 2018 Jul 20;23(7):1798.
112. Schmidtke M, Wutzler P, Zieger R, Riabova OB, Makarov VA. New pleconaril and [(biphenyloxy) propyl] isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. Antiviral research. 2009 Jan 1;81(1):56-63.
113. Yang ZB, Li P, He YJ. Design, synthesis, and bioactivity evaluation of novel isoxazole-amide derivatives containing an acylhydrazone moiety as new active antiviral agents. Molecules. 2019 Oct 19;24(20):3766.
114. Joseph L, George M. Evaluation of in vivo and in vitro anti-inflammatory activity of novel isoxazole series. Eur Int J Sci Technol. 2016;5(3):35-42.
115. Abu-Hashem AA, El-Shazly M. Synthesis of new isoxazole-, pyridazine-, pyrimidopyrazines and their anti-inflammatory and analgesic activity. Medicinal Chemistry. 2018 Jun 1;14(4):356-71.
116. Kamal YT, Gautam GK, Mishra AK, Parveen BR, Kumar A, Singh M, Singh H. Synthesis, characterization, molecular docking and pharmacological evaluation of isoxazole derivatives as potent anti-inflammatory agents. Heliyon. 2024 Nov 30;10(22).
117. Burra S, Voora V, Rao CP, Kumar PV, Kancha RK, Krupadanam GD. Synthesis of novel forskolin isoxazole derivatives with potent anti-cancer activity against breast cancer cell lines. Bioorganic & Medicinal Chemistry Letters. 2017 Sep 15;27(18):4314-8.
118. Hawash M, Jaradat N, Bawwab N, Salem K, Arafat H, Hajyousef Y, Shtayeh T, Sobuh S. Design, synthesis, and biological evaluation of phenyl-isoxazole-carboxamide derivatives as anticancer agents. Heterocyclic Communications. 2021 Dec 27;27(1):133-41.
119. Yong JP, Lu CZ, Wu X. Potential anticancer agents. I. Synthesis of isoxazole moiety containing quinazoline derivatives and preliminarily in vitro anticancer activity. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2015 Jan 1;15(1):131-6.
120. Goulding KH, Yung KM, Hall AM, Cremlyn RJ. The antifungal activity of some sulphonyl derivatives of isoxazole, pyrazole, thiazole and thiophene. Pesticide Science. 1983 Apr;14(2):158-66.
121. Nagaraja Rao HK, Poojary B, Mohan Kumar KK, Chandrasehar G, Sannathammegowda K, Pandith A. Novel Isoxazolylpyrimidine Derivatives: Design, Synthesis, Antifungal Activity and In-Silico Studies. Asian Journal of Organic Chemistry. 2024 May;13(5):e202400021.
122. Zhang DW, Lin F, Li BC, Liu HW, Zhao TQ, Zhang YM,

Gu Q. Efficient synthesis of bis-isoxazole ethers via 1, 3-dipolar cycloaddition catalysed by Zn/Zn2+ and their antifungal activities. Chemical Papers. 2015 Nov;69(11):1500-11.

123. Badrey MG, Gomha SM. Synthesis and antibacterial activity of fused isoxazole derivatives using grinding method. Int J Pharm Pharm Sci. 2014;6(7):236-9.
124. Bommagani MB, Yerrabelly JR, Chitneni M, Thalari G, Vadiyala NR, Boda SK, Chitneni PR. Synthesis and antibacterial activity of novel cinnoline-isoxazole derivatives. Chemical Data Collections. 2021 Feb 1;31:100629.
125. Thakur A, Verma M, Setia P, Bharti R, Sharma R, Sharma A, Negi NP, Anand V, Bansal R. DFT analysis and in vitro studies of isoxazole derivatives as potent antioxidant and antibacterial agents synthesized via one-pot methodology: A. Thakur et al. Research on Chemical Intermediates. 2023 Mar;49(3):859-83.
126. Hawash M, Jaradat N, Abualhasan M, Thaher M, Sawalhi R, Younes N, Shanaa A, Nuseirat M, Mousa A. In vitro and in vivo assessment of the antioxidant potential of isoxazole derivatives. Scientific Reports. 2022 Oct 29;12(1):18223.
127. Shaik A, Bhandare RR, Palleapati K, Nissankararao S, Kancharlapalli V, Shaik S. Antimicrobial, antioxidant, and anticancer activities of some novel isoxazole ring containing chalcone and dihydropyrazole derivatives. Molecules. 2020 Feb 26;25(5):1047.
128. Alam W, Khan H, Jan MS, W. Darwish H, Daglia M, A. Elhenawy A. In vitro 5-LOX inhibitory and antioxidant potential of isoxazole derivatives. Plos one. 2024 Oct 4;19(10):e0297398.
129. Shukla PK, Verma A, Mishra P. Significance of nitrogen heterocyclic nuclei in the search of pharmacological active compounds. New perspective in agricultural and human health. 2017;100.
130. Haino T, Hirao T. Supramolecular polymerization and functions of isoxazole ring monomers. Chemistry Letters. 2020 May;49(5):574-84.
131. Mohsin NU, Irfan M. Selective cyclooxygenase-2 inhibitors: A review of recent chemical scaffolds with promising anti-inflammatory and COX-2 inhibitory activities. Medicinal Chemistry Research. 2020 May;29(5):809-30.
132. Jena S, Dutta J, Tulsiyan KD, Sahu AK, Choudhury SS, Biswal HS. Noncovalent interactions in proteins and nucleic acids: beyond hydrogen bonding and π-stacking. Chemical Society Reviews. 2022;51(11):4261-86.
133. Lv XW, Gong J, Wang S, Yan X, Sun C, Hu X, Lai Z, Liu Y, Wang H, Yuan ZY, Geng J. Engineering Orbital Hybridization in Advanced Electrocatalysts for Energy Conversion: Fundamentals, Modulations, and Perspectives. Advanced Energy Materials. 2025 Apr 15:2501129.
134. Zhu J, Mo J, Lin HZ, Chen Y, Sun HP. The recent progress of isoxazole in medicinal chemistry. Bioorganic & Medicinal Chemistry. 2018 Jul 23;26(12):3065-75.
135. Zimecki M, Bąchor U, Mączyński M. Isoxazole derivatives as regulators of immune functions. Molecules. 2018 Oct 22;23(10):2724.
136. Rostami H, Haddadi MH. Benzimidazole derivatives: A versatile scaffold for drug development against Helicobacter pylori-related diseases. Fundamental & Clinical Pharmacology. 2022 Dec;36(6):930-43.
137. Ali AM, Tawfik SS, Mostafa AS, Massoud MA. Benzimidazole-based protein kinase inhibitors: Current perspectives in targeted cancer therapy. Chemical Biology & Drug Design. 2022 Nov;100(5):656-73.
138. Baig N, Kammakakam I, Falath W. Nanomaterials: A review of synthesis methods, properties, recent progress, and challenges. Materials advances. 2021;2(6):1821-71.
139. Visan AI, Negut I. Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery. Life. 2024 Feb 7;14(2):233.
140. Malik U, Pal D. Cancer-Fighting Isoxazole Compounds: Sourcing Nature's Potential and Synthetic Advancements-A Comprehensive Review. ES Food & Agroforestry. 2023 Dec 13;15:1052.
141. Gangwal A, Lavecchia A. Artificial intelligence in natural product drug discovery: current applications and future perspectives. Journal of medicinal chemistry. 2025 Feb 7;68(4):3948-69.